Secukinumab/Pediatric Psoriasis CAIN457A2310

AMNOG Dossier Sensitivity Analysis C

Date: 24.08.2020

Document Status: Final

Author: Monika Schwager, Winicker Norimed GmbH

Table of Contents

Tables

Patient Disposition and Baseline Characteristics

1.1 Patient Disposition and Compliance (RAN, FAS)

	Treatment Groups			
Disposition/Reason	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Randomized (RAN)	**31 (100.0)**	**28 (100.0)**	**26 (100.0)**	**85 (100.0)**
Full Analysis Set (FAS)	**31 (100.0)**	**28 (100.0)**	**26 (100.0)**	**85 (100.0)**
Study discontinuation during induction period	**1 (3.2)**	**0 (0.0)**	**0 (0.0)**	**1 (1.2)**
Reasons for study discontinuation during induction period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	1 (3.2)	0 (0.0)	0 (0.0)	1 (1.2)
Study discontinuation during maintenance period	**0 (0.0)**	**0 (0.0)**	**1 (3.8)**	**1 (1.2)**
Reasons for study discontinuation during maintenance period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	1 (3.8)	1 (1.2)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study drug during induction period				
Received study drug	31 (100.0)	28 (100.0)	26 (100.0)	85 (100.0)
Did not receive study drug	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Completed induction period on double-blind study drug	30 (96.8)	28 (100.0)	26 (100.0)	84 (98.8)
Prematurely discontinued double-blind study drug during induction period	1 (3.2)	0 (0.0)	0 (0.0)	1 (1.2)
Primary reason for premature discontinuation from double-blind study drug during induction period				
Adverse event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lack of efficacy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	1 (3.2)	0 (0.0)	0 (0.0)	1 (1.2)

	Treatment Groups			
Disposition/Reason	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Study drug during maintenance period				
Received study drug	30 (96.8)	28 (100.0)	26 (100.0)	84 (98.8)
Did not receive study drug	1 (3.2)	0 (0.0)	0 (0.0)	1 (1.2)
Completed maintenance period on double-blind study drug	29 (93.5)	27 (96.4)	21 (80.8)	77 (90.6)
Prematurely discontinued double-blind study drug during maintenance period	1 (3.2)	1 (3.6)	5 (19.2)	7 (8.2)
Primary reason for premature discontinuation from double-blind study drug during maintenance period				
Adverse event	1 (3.2)	0 (0.0)	1 (3.8)	2 (2.4)
Lack of efficacy	0 (0.0)	1 (3.6)	3 (11.5)	4 (4.7)
Pregnancy	0 (0.0)	0 (0.0)	1 (3.8)	1 (1.2)
Protocol deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Subject/guardian decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Withdrawal of informed consent	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Protocol deviations during induction period				
Subject with at least one protocol deviation	7 (22.6)	7 (25.0)	12 (46.2)	26 (30.6)
Selection criteria not met	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	1 (3.2)	0 (0.0)	4 (15.4)	5 (5.9)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	6 (19.4)	7 (25.0)	8 (30.8)	21 (24.7)
Protocol deviations during maintenance period				
Subject with at least one protocol deviation	9 (29.0)	11 (39.3)	14 (53.8)	34 (40.0)
Selection criteria not met	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Treatment deviation	6 (19.4)	6 (21.4)	11 (42.3)	23 (27.1)
Prohibited concomitant medication	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other deviation	5 (16.1)	5 (17.9)	4 (15.4)	14 (16.5)

1.2 Length of Study Participation (FAS)

	Treatment Groups			
Subgroups	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Study participation in induction period				
Mean ± SD (in days)	84.7 ± 15.1	86.3 ± 8.4	86.6 ± 5.0	85.8 ± 10.6
Median (in days)	85.0	85.0	85.0	85.0
Range (in days)	9 - 106	78 - 127	81 - 108	9 - 127
Study participation in maintenance period				
Mean ± SD (in days)	276.6 ± 20.8	279.1 ± 13.6	245.9 ± 85.0	267.9 ± 51.1
Median (in days)	281.0	281.0	281.0	281.0
Range (in days)	175 - 309	223 - 309	24 - 304	24 - 309
Study participation in induction+maintenance period				
Mean ± SD (in days)	351.4 ± 66.6	364.4 ± 14.2	331.5 ± 82.5	349.6 ± 62.0
Median (in days)	365.0	365.0	365.0	365.0
Range (in days)	9 - 393	301 - 386	113 - 388	9 - 393

Duration of study participation in each period is defined as the time from the first entry up to the last entry in the respective period.

1.3 Characterization of Study Population, Demographic Characteristics (FAS)

	Treatment Groups			
Patient characteristics	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Age (years)				
Mean ± SD	13.5 ± 3.2	13.4 ± 3.3	13.5 ± 2.9	13.5 ± 3.1
Median	15.0	14.5	14.0	14.0
Range	7 - 17	6 - 17	6 - 17	6 - 17
Age group (years), n(%)				
<12	8 (25.8)	6 (21.4)	6 (23.1)	20 (23.5)
≥12	23 (74.2)	22 (78.6)	20 (76.9)	65 (76.5)
Sex, n(%)				
Male	9 (29.0)	13 (46.4)	10 (38.5)	32 (37.6)
Female	22 (71.0)	15 (53.6)	16 (61.5)	53 (62.4)
Weight (kg)				
Mean ± SD	51.9 ± 16.6	54.8 ± 21.4	52.2 ± 19.9	53.0 ± 19.1
Median	50.8	51.0	50.9	50.8
Range	21 - 85	20.5 - 116	20.5 - 105.5	20.5 - 116
Weight group (kg), n(%)				
<25	2 (6.5)	2 (7.1)	3 (11.5)	7 (8.2)
≥25 - <50	13 (41.9)	10 (35.7)	8 (30.8)	31 (36.5)
≥50	16 (51.6)	16 (57.1)	15 (57.7)	47 (55.3)
Height (cm)				
Mean ± SD	157.5 ± 15.6	156.9 ± 19.8	154.4 ± 17.4	156.3 ± 17.5
Median	160.0	160.0	158.0	160.0
Range	121 - 185	115 - 194	118 - 183	115 - 194
BMI (kg/m)				
Mean ± SD	20.3 ± 3.8	21.5 ± 4.5	21.0 ± 4.6	20.9 ± 4.2
Median	19.6	20.8	21.1	20.4
Range	14.1 - 30.7	14.4 - 33.9	14.7 - 31.5	14.1 - 33.9
Child bearing status, n(%)				
Able to bear children	13 (41.9)	10 (35.7)	11 (42.3)	34 (40.0)
Premenarche	9 (29.0)	5 (17.9)	5 (19.2)	19 (22.4)
Race, n(%)				
Caucasian	27 (87.1)	25 (89.3)	20 (76.9)	72 (84.7)
Black	1 (3.2)	1 (3.6)	0 (0.0)	2 (2.4)
Asian	1 (3.2)	1 (3.6)	2 (7.7)	4 (4.7)
Native American	1 (3.2)	1 (3.6)	4 (15.4)	6 (7.1)
Other	1 (3.2)	0 (0.0)	0 (0.0)	1 (1.2)

	Treatment Groups			
Patient characteristics	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Ethnicity, n(%)				
Hispanic/Latino	2 (6.5)	2 (7.1)	4 (15.4)	8 (9.4)
Not Hispanic or Latino	23 (74.2)	23 (82.1)	17 (65.4)	63 (74.1)
Unknown	3 (9.7)	2 (7.1)	2 (7.7)	7 (8.2)
Region, n(%)				
Africa	1 (3.2)	1 (3.6)	3 (11.5)	5 (5.9)
America	2 (6.5)	3 (10.7)	4 (15.4)	9 (10.6)
Asia	7 (22.6)	1 (3.6)	3 (11.5)	11 (12.9)
Europe	21 (67.7)	23 (82.1)	16 (61.5)	60 (70.6)

1.4 Disease History and Prior Medication (FAS)

	Treatment Groups			
Disease history	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Diagnosis of plaque-type psoriasis, n(%)				
Yes	31 (100.0)	28 (100.0)	26 (100.0)	85 (100.0)
Time since first diagnosis of plaque-type psoriasis (years)				
Mean ± SD	5.7 ± 4.4	4.9 ± 3.8	5.2 ± 4.3	5.3 ± 4.1
Median	4.8	3.3	4.0	4.1
Range	0.3 - 17.0	0.4 - 14.3	0.5 - 14.0	0.3 - 17.0
Diagnosis of psoriatic arthritis, n(%)				
Yes	4 (12.9)	2 (7.1)	3 (11.5)	9 (10.6)
No	27 (87.1)	26 (92.9)	23 (88.5)	76 (89.4)
Time since first diagnosis of psoriatic arthritis (years)				
Mean ± SD	5.4 ± 3.5	0.7 ± 0.1	1.4 ± 1.1	3.0 ± 3.2
Median	5.1	0.7	1.2	1.6
Range	1.6 - 9.7	0.7 - 0.8	0.3 - 2.6	0.3 - 9.7
Previous psoriasis therapies, n(%)				
Yes	31 (100.0)	28 (100.0)	26 (100.0)	85 (100.0)
Previous systemic therapies, n(%)				
Yes	25 (80.6)	19 (67.9)	16 (61.5)	60 (70.6)
No	6 (19.4)	9 (32.1)	10 (38.5)	25 (29.4)
Failure	24 (77.4)	17 (60.7)	14 (53.8)	55 (64.7)
no failure	1 (3.2)	2 (7.1)	2 (7.7)	5 (5.9)
Previous phototherapy or photochemotherapy, n(%)				
Yes	16 (51.6)	20 (71.4)	19 (73.1)	55 (64.7)
No	15 (48.4)	8 (28.6)	7 (26.9)	30 (35.3)
Failure	15 (48.4)	17 (60.7)	18 (69.2)	50 (58.8)
no failure	1 (3.2)	3 (10.7)	1 (3.8)	5 (5.9)
Previous topical therapy, n(%)				
Yes	23 (74.2)	24 (85.7)	23 (88.5)	70 (82.4)
No	8 (25.8)	4 (14.3)	3 (11.5)	15 (17.6)
Failure	21 (67.7)	20 (71.4)	19 (73.1)	60 (70.6)
no failure	2 (6.5)	4 (14.3)	4 (15.4)	10 (11.8)

	Treatment Groups			
Disease history	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Failure of at least one systemic therapy or phototherapy or photochemotherapy, n(%)				
Yes	31 (100.0)	28 (100.0)	26 (100.0)	85 (100.0)

1.5 Baseline Disease Characteristics (FAS)

	Treatment Groups			
Baseline disease characteristics	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Baseline PASI score				
Mean ± SD	28.1 ± 7.5	29.1 ± 9.5	29.3 ± 10.4	28.8 ± 9.0
Median	25.2	26.2	25.3	25.9
Range	20.2 - 48	20.2 - 58.8	20.1 - 59.8	20.1 - 59.8
Baseline PASI, n(%)				
>20	31 (100.0)	28 (100.0)	26 (100.0)	85 (100.0)
Baseline total BSA				
Mean ± SD	37.7 ± 15.1	40.8 ± 18.7	44.2 ± 23.0	40.7 ± 18.9
Median	36.8	36.5	34.0	36.1
Range	12 - 72.5	16 - 94	13.1 - 90.5	12 - 94
Baseline IGA mod 2011 score, n(%)				
4 = Severe disease	31 (100.0)	28 (100.0)	26 (100.0)	85 (100.0)

1.6 Subgroups (FAS)

	Treatment Groups			
Subgroups	**SEC low (N=31)**	**SEC high (N=28)**	**ETA (N=26)**	**Total (N=85)**
Subgroup Age, n (%)				
< 12 years	8 (25.8)	6 (21.4)	6 (23.1)	20 (23.5)
≥ 12 years	23 (74.2)	22 (78.6)	20 (76.9)	65 (76.5)
Subgroup Gender, n (%)				
Male	9 (29.0)	13 (46.4)	10 (38.5)	32 (37.6)
Female	22 (71.0)	15 (53.6)	16 (61.5)	53 (62.4)
Subgroup Disease Severity, n (%)				
Baseline PASI ≤ median	16 (51.6)	12 (42.9)	13 (50.0)	41 (48.2)
Baseline PASI > median	15 (48.4)	16 (57.1)	13 (50.0)	44 (51.8)
Subgroup Region, n (%)				
Africa	1 (3.2)	1 (3.6)	3 (11.5)	5 (5.9)
America	2 (6.5)	3 (10.7)	4 (15.4)	9 (10.6)
Asia	7 (22.6)	1 (3.6)	3 (11.5)	11 (12.9)
Europe	21 (67.7)	23 (82.1)	16 (61.5)	60 (70.6)
Subgroup Region - Europe vs. Others, n (%)				
Europe	21 (67.7)	23 (82.1)	16 (61.5)	60 (70.6)
Others	10 (32.3)	5 (17.9)	10 (38.5)	25 (29.4)
Subgroup Weight, n (%)				
< 25 kg	2 (6.5)	2 (7.1)	3 (11.5)	7 (8.2)
≥ 25 kg - < 50 kg	13 (41.9)	10 (35.7)	8 (30.8)	31 (36.5)
≥ 50 kg	16 (51.6)	16 (57.1)	15 (57.7)	47 (55.3)
Subgroup Weight - < 50kg vs. ≥ 50 kg, n (%)				
< 50 kg	15 (48.4)	12 (42.9)	11 (42.3)	38 (44.7)
≥ 50 kg	16 (51.6)	16 (57.1)	15 (57.7)	47 (55.3)
Subgroup Previous Systemic Therapy, n (%)				
No	6 (19.4)	9 (32.1)	10 (38.5)	25 (29.4)
Yes	25 (80.6)	19 (67.9)	16 (61.5)	60 (70.6)

Efficacy and safety subgroup analysis is displayed for all subgrouping factors with at least 10 patients in each subgroup.

Safety Analysis

S.1.1 Adverse Events, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
Any AE, n (%)	25 (80.6)	24 (85.7)	24 (92.3)			
SEC low vs. ETA				0.35 [0.03; 2.23] 0.382	0.87 [0.71; 1.07] 0.269	-0.12 [-0.29; 0.06] 0.186
SEC high vs. ETA				0.51 [0.04; 3.92] 0.742	0.93 [0.77; 1.12] 0.670	-0.07 [-0.23; 0.10] 0.434
Any AE, disease specific events excluded, n (%)	25 (80.6)	24 (85.7)	24 (92.3)			
SEC low vs. ETA				0.35 [0.03; 2.23] 0.382	0.87 [0.71; 1.07] 0.269	-0.12 [-0.29; 0.06] 0.186
SEC high vs. ETA				0.51 [0.04; 3.92] 0.742	0.93 [0.77; 1.12] 0.670	-0.07 [-0.23; 0.10] 0.434
Any SAE, n (%)	3 (9.7)	3 (10.7)	5 (19.2)			
SEC low vs. ETA				0.46 [0.06; 2.65] 0.514	0.50 [0.13; 1.91] 0.448	-0.10 [-0.28; 0.09] 0.308
SEC high vs. ETA				0.51 [0.07; 2.98] 0.620	0.56 [0.15; 2.10] 0.460	-0.09 [-0.28; 0.10] 0.379
Any SAE, disease specific events excluded, n (%)	3 (9.7)	3 (10.7)	5 (19.2)			
SEC low vs. ETA				0.46 [0.06; 2.65] 0.514	0.50 [0.13; 1.91] 0.448	-0.10 [-0.28; 0.09] 0.308
SEC high vs. ETA				0.51 [0.07; 2.98] 0.620	0.56 [0.15; 2.10] 0.460	-0.09 [-0.28; 0.10] 0.379
Any severe AE, n (%)	1 (3.2)	2 (7.1)	4 (15.4)			
SEC low vs. ETA				0.19 [<0.01; 2.08] 0.253	0.21 [0.02; 1.76] 0.167	-0.12 [-0.27; 0.03] 0.117
SEC high vs. ETA				0.43 [0.04; 3.33] 0.598	0.46 [0.09; 2.33] 0.413	-0.08 [-0.25; 0.09] 0.337

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE, disease specific events excluded, n (%)	1 (3.2)	2 (7.1)	4 (15.4)			
SEC low vs. ETA				0.19 [<0.01; 2.08] 0.253	0.21 [0.02; 1.76] 0.167	-0.12 [-0.27; 0.03] 0.117
SEC high vs. ETA				0.43 [0.04; 3.33] 0.598	0.46 [0.09; 2.33] 0.413	-0.08 [-0.25; 0.09] 0.337
Any AE leading to study discontinuation, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation, n (%)	1 (3.2)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

List of Excluded Disease-Specific SOC/Preferred Terms

Preferred Terms (grouped by disease-specific event category)
General disorders and administration site conditions
Fatigue
Malaise
Musculoskeletal and connective tissue disorders
Arthralgia
Back pain
Joint swelling
Pain in extremity
Skin and subcutaneous tissue disorders
Dry skin
Erythema
Pruritus
Pruritus generalised
Psoriasis
Skin fissures
Skin irritation

S.1.2 Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
Any adverse event, n (%)	25 (80.6)	24 (85.7)	24 (92.3)			
SEC low vs. ETA				0.35 [0.03; 2.23] 0.382	0.87 [0.71; 1.07] 0.269	-0.12 [-0.29; 0.06] 0.186
SEC high vs. ETA				0.51 [0.04; 3.92] 0.742	0.93 [0.77; 1.12] 0.670	-0.07 [-0.23; 0.10] 0.434
Mild, n (%)	24 (77.4)	23 (82.1)	22 (84.6)			
SEC low vs. ETA				0.63 [0.12; 2.88] 0.733	0.91 [0.71; 1.18] 0.738	-0.07 [-0.27; 0.13] 0.486
SEC high vs. ETA				0.84 [0.15; 4.48] 1.000	0.97 [0.77; 1.23] 1.000	-0.02 [-0.22; 0.17] 0.807
Moderate, n (%)	12 (38.7)	11 (39.3)	16 (61.5)			
SEC low vs. ETA				0.40 [0.12; 1.30] 0.146	0.63 [0.37; 1.08] 0.113	-0.23 [-0.48; 0.03] 0.078
SEC high vs. ETA				0.41 [0.12; 1.37] 0.173	0.64 [0.37; 1.11] 0.173	-0.22 [-0.48; 0.04] 0.094
Severe, n (%)	1 (3.2)	2 (7.1)	4 (15.4)			
SEC low vs. ETA				0.19 [<0.01; 2.08] 0.253	0.21 [0.02; 1.76] 0.167	-0.12 [-0.27; 0.03] 0.117
SEC high vs. ETA				0.43 [0.04; 3.33] 0.598	0.46 [0.09; 2.33] 0.413	-0.08 [-0.25; 0.09] 0.337
Infections and infestations, n (%)	21 (67.7)	20 (71.4)	19 (73.1)			
SEC low vs. ETA				0.78 [0.21; 2.80] 0.886	0.93 [0.66; 1.30] 0.774	-0.05 [-0.29; 0.18] 0.659
SEC high vs. ETA				0.92 [0.23; 3.57] 1.000	0.98 [0.70; 1.36] 1.000	-0.02 [-0.26; 0.22] 0.892

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	19 (61.3)	19 (67.9)	17 (65.4)			
SEC low vs. ETA				0.84 [0.25; 2.82] 0.967	0.94 [0.63; 1.39] 0.789	-0.04 [-0.29; 0.21] 0.749
SEC high vs. ETA				1.12 [0.31; 4.03] 1.000	1.04 [0.71; 1.52] 1.000	0.02 [-0.23; 0.28] 0.847
Moderate, n (%)	8 (25.8)	9 (32.1)	8 (30.8)			
SEC low vs. ETA				0.79 [0.21; 2.93] 0.902	0.84 [0.37; 1.92] 0.771	-0.05 [-0.28; 0.19] 0.679
SEC high vs. ETA				1.06 [0.29; 3.96] 1.000	1.04 [0.47; 2.30] 1.000	0.01 [-0.23; 0.26] 0.913
Severe, n (%)	1 (3.2)	2 (7.1)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				1.90 [0.09; 117.92] 1.000	1.86 [0.18; 19.29] 1.000	0.03 [-0.09; 0.15] 0.592
Nasopharyngitis, n (%)	9 (29.0)	12 (42.9)	8 (30.8)			
SEC low vs. ETA				0.92 [0.25; 3.38] 1.000	0.94 [0.43; 2.09] 1.000	-0.02 [-0.26; 0.22] 0.887
SEC high vs. ETA				1.67 [0.48; 6.06] 0.525	1.39 [0.68; 2.86] 0.408	0.12 [-0.13; 0.38] 0.353
Mild, n (%)	8 (25.8)	11 (39.3)	7 (26.9)			
SEC low vs. ETA				0.95 [0.25; 3.68] 1.000	0.96 [0.40; 2.29] 1.000	-0.01 [-0.24; 0.22] 0.924
SEC high vs. ETA				1.74 [0.48; 6.62] 0.501	1.46 [0.67; 3.19] 0.395	0.12 [-0.12; 0.37] 0.330
Moderate, n (%)	1 (3.2)	2 (7.1)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				0.92 [0.06; 13.69] 1.000	0.93 [0.14; 6.12] 1.000	-0.01 [-0.15; 0.13] 0.939

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Gastroenteritis, n (%)	4 (12.9)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				3.63 [0.33; 189.55] 0.472	3.35 [0.40; 28.19] 0.362	0.09 [-0.05; 0.23] 0.202
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Mild, n (%)	3 (9.7)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				2.64 [0.20; 146.14] 0.751	2.52 [0.28; 22.76] 0.617	0.06 [-0.07; 0.19] 0.371
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Moderate, n (%)	1 (3.2)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.84 [0.02; >999.99] 1.000	2.53 [0.11; 59.63] 1.000	0.03 [-0.03; 0.09] 0.309
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Pharyngitis, n (%)	3 (9.7)	3 (10.7)	3 (11.5)			
SEC low vs. ETA				0.82 [0.10; 6.76] 1.000	0.84 [0.18; 3.81] 1.000	-0.02 [-0.18; 0.14] 0.821
SEC high vs. ETA				0.92 [0.11; 7.59] 1.000	0.93 [0.21; 4.20] 1.000	-0.01 [-0.18; 0.16] 0.923
Mild, n (%)	2 (6.5)	3 (10.7)	1 (3.8)			
SEC low vs. ETA				1.71 [0.08; 105.73] 1.000	1.68 [0.16; 17.47] 1.000	0.03 [-0.09; 0.14] 0.654
SEC high vs. ETA				2.94 [0.22; 163.67] 0.668	2.79 [0.31; 25.12] 0.612	0.07 [-0.07; 0.21] 0.323

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	1 (3.2)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Rhinitis, n (%)	2 (6.5)	3 (10.7)	1 (3.8)			
SEC low vs. ETA				1.71 [0.08; 105.73] 1.000	1.68 [0.16; 17.47] 1.000	0.03 [-0.09; 0.14] 0.654
SEC high vs. ETA				2.94 [0.22; 163.67] 0.668	2.79 [0.31; 25.12] 0.612	0.07 [-0.07; 0.21] 0.323
Mild, n (%)	1 (3.2)	3 (10.7)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				2.94 [0.22; 163.67] 0.668	2.79 [0.31; 25.12] 0.612	0.07 [-0.07; 0.21] 0.323
Moderate, n (%)	1 (3.2)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.84 [0.02; >999.99] 1.000	2.53 [0.11; 59.63] 1.000	0.03 [-0.03; 0.09] 0.309
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Oral herpes, n (%)	1 (3.2)	1 (3.6)	3 (11.5)			
SEC low vs. ETA				0.26 [<0.01; 3.50] 0.484	0.28 [0.03; 2.53] 0.322	-0.08 [-0.22; 0.05] 0.237
SEC high vs. ETA				0.29 [<0.01; 3.90] 0.555	0.31 [0.03; 2.79] 0.342	-0.08 [-0.22; 0.06] 0.267

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	1 (3.2)	1 (3.6)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				0.45 [<0.01; 9.18] 0.943	0.46 [0.04; 4.82] 0.604	-0.04 [-0.16; 0.08] 0.513
Moderate, n (%)	0 (0.0)	1 (3.6)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [0.01; 75.55] 1.000	0.93 [0.06; 14.10] 1.000	-0.00 [-0.10; 0.10] 0.957
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Gastrointestinal disorders, n (%)	9 (29.0)	11 (39.3)	10 (38.5)			
SEC low vs. ETA				0.66 [0.19; 2.28] 0.637	0.75 [0.36; 1.57] 0.575	-0.09 [-0.34; 0.15] 0.452
SEC high vs. ETA				1.03 [0.30; 3.56] 1.000	1.02 [0.52; 2.00] 1.000	0.01 [-0.25; 0.27] 0.950
Mild, n (%)	9 (29.0)	11 (39.3)	5 (19.2)			
SEC low vs. ETA				1.70 [0.43; 7.59] 0.588	1.51 [0.58; 3.95] 0.539	0.10 [-0.12; 0.32] 0.383
SEC high vs. ETA				2.67 [0.69; 11.82] 0.188	2.04 [0.82; 5.09] 0.141	0.20 [-0.04; 0.44] 0.096
Moderate, n (%)	2 (6.5)	2 (7.1)	5 (19.2)			
SEC low vs. ETA				0.30 [0.03; 2.02] 0.290	0.34 [0.07; 1.59] 0.228	-0.13 [-0.30; 0.05] 0.151
SEC high vs. ETA				0.33 [0.03; 2.27] 0.361	0.37 [0.08; 1.75] 0.243	-0.12 [-0.30; 0.06] 0.186

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Abdominal pain, n (%)	3 (9.7)	3 (10.7)	5 (19.2)			
SEC low vs. ETA				0.46 [0.06; 2.65] 0.514	0.50 [0.13; 1.91] 0.448	-0.10 [-0.28; 0.09] 0.308
SEC high vs. ETA				0.51 [0.07; 2.98] 0.620	0.56 [0.15; 2.10] 0.460	-0.09 [-0.28; 0.10] 0.379
Mild, n (%)	2 (6.5)	3 (10.7)	3 (11.5)			
SEC low vs. ETA				0.53 [0.04; 5.08] 0.830	0.56 [0.10; 3.10] 0.651	-0.05 [-0.20; 0.10] 0.507
SEC high vs. ETA				0.92 [0.11; 7.59] 1.000	0.93 [0.21; 4.20] 1.000	-0.01 [-0.18; 0.16] 0.923
Moderate, n (%)	1 (3.2)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Diarrhoea, n (%)	3 (9.7)	4 (14.3)	1 (3.8)			
SEC low vs. ETA				2.64 [0.20; 146.14] 0.751	2.52 [0.28; 22.76] 0.617	0.06 [-0.07; 0.19] 0.371
SEC high vs. ETA				4.07 [0.37; 213.24] 0.399	3.71 [0.44; 31.11] 0.353	0.10 [-0.04; 0.25] 0.170

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	3 (9.7)	4 (14.3)	1 (3.8)			
SEC low vs. ETA				2.64 [0.20; 146.14] 0.751	2.52 [0.28; 22.76] 0.617	0.06 [-0.07; 0.19] 0.371
SEC high vs. ETA				4.07 [0.37; 213.24] 0.399	3.71 [0.44; 31.11] 0.353	0.10 [-0.04; 0.25] 0.170
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vomiting, n (%)	1 (3.2)	4 (14.3)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				4.07 [0.37; 213.24] 0.399	3.71 [0.44; 31.11] 0.353	0.10 [-0.04; 0.25] 0.170
Mild, n (%)	1 (3.2)	4 (14.3)	0 (0.0)			
SEC low vs. ETA				0.84 [0.02; >999.99] 1.000	2.53 [0.11; 59.63] 1.000	0.03 [-0.03; 0.09] 0.309
SEC high vs. ETA				5.40 [0.64; >999.99] 0.129	8.38 [0.47; 148.44] 0.112	0.14 [0.01; 0.27] 0.031
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Abdominal pain upper, n (%)	1 (3.2)	3 (10.7)	3 (11.5)			
SEC low vs. ETA				0.26 [<0.01; 3.50] 0.484	0.28 [0.03; 2.53] 0.322	-0.08 [-0.22; 0.05] 0.237
SEC high vs. ETA				0.92 [0.11; 7.59] 1.000	0.93 [0.21; 4.20] 1.000	-0.01 [-0.18; 0.16] 0.923
Mild, n (%)	1 (3.2)	2 (7.1)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				0.92 [0.06; 13.69] 1.000	0.93 [0.14; 6.12] 1.000	-0.01 [-0.15; 0.13] 0.939
Moderate, n (%)	0 (0.0)	1 (3.6)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [0.01; 75.55] 1.000	0.93 [0.06; 14.10] 1.000	-0.00 [-0.10; 0.10] 0.957
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Nausea, n (%)	2 (6.5)	2 (7.1)	3 (11.5)			
SEC low vs. ETA				0.53 [0.04; 5.08] 0.830	0.56 [0.10; 3.10] 0.651	-0.05 [-0.20; 0.10] 0.507
SEC high vs. ETA				0.60 [0.05; 5.68] 0.928	0.62 [0.11; 3.41] 0.663	-0.04 [-0.20; 0.11] 0.580
Mild, n (%)	1 (3.2)	2 (7.1)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				0.92 [0.06; 13.69] 1.000	0.93 [0.14; 6.12] 1.000	-0.01 [-0.15; 0.13] 0.939

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	1 (3.2)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Skin and subcutaneous tissue disorders, n (%)	11 (35.5)	11 (39.3)	8 (30.8)			
SEC low vs. ETA				1.23 [0.36; 4.41] 0.928	1.15 [0.55; 2.43] 0.782	0.05 [-0.20; 0.29] 0.706
SEC high vs. ETA				1.45 [0.41; 5.27] 0.713	1.28 [0.61; 2.67] 0.577	0.09 [-0.17; 0.34] 0.510
Mild, n (%)	10 (32.3)	8 (28.6)	6 (23.1)			
SEC low vs. ETA				1.57 [0.42; 6.33] 0.640	1.40 [0.59; 3.33] 0.558	0.09 [-0.14; 0.32] 0.436
SEC high vs. ETA				1.33 [0.33; 5.57] 0.883	1.24 [0.50; 3.09] 0.760	0.05 [-0.18; 0.29] 0.644
Moderate, n (%)	3 (9.7)	4 (14.3)	1 (3.8)			
SEC low vs. ETA				2.64 [0.20; 146.14] 0.751	2.52 [0.28; 22.76] 0.617	0.06 [-0.07; 0.19] 0.371
SEC high vs. ETA				4.07 [0.37; 213.24] 0.399	3.71 [0.44; 31.11] 0.353	0.10 [-0.04; 0.25] 0.170
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Eczema, n (%)	1 (3.2)	3 (10.7)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				2.94 [0.22; 163.67] 0.668	2.79 [0.31; 25.12] 0.612	0.07 [-0.07; 0.21] 0.323
Mild, n (%)	1 (3.2)	2 (7.1)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				1.90 [0.09; 117.92] 1.000	1.86 [0.18; 19.29] 1.000	0.03 [-0.09; 0.15] 0.592
Moderate, n (%)	0 (0.0)	1 (3.6)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.93 [0.02; >999.99] 1.000	2.79 [0.12; 65.67] 1.000	0.04 [-0.03; 0.10] 0.309
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Respiratory, thoracic and mediastinal disorders, n (%)	3 (9.7)	9 (32.1)	4 (15.4)			
SEC low vs. ETA				0.59 [0.08; 3.92] 0.799	0.63 [0.15; 2.56] 0.691	-0.06 [-0.23; 0.12] 0.519
SEC high vs. ETA				2.56 [0.59; 13.27] 0.262	2.09 [0.73; 5.97] 0.207	0.17 [-0.05; 0.39] 0.138
Mild, n (%)	3 (9.7)	9 (32.1)	4 (15.4)			
SEC low vs. ETA				0.59 [0.08; 3.92] 0.799	0.63 [0.15; 2.56] 0.691	-0.06 [-0.23; 0.12] 0.519
SEC high vs. ETA				2.56 [0.59; 13.27] 0.262	2.09 [0.73; 5.97] 0.207	0.17 [-0.05; 0.39] 0.138
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Oropharyngeal pain, n (%)	0 (0.0)	4 (14.3)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				4.07 [0.37; 213.24] 0.399	3.71 [0.44; 31.11] 0.353	0.10 [-0.04; 0.25] 0.170
Mild, n (%)	0 (0.0)	4 (14.3)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				4.07 [0.37; 213.24] 0.399	3.71 [0.44; 31.11] 0.353	0.10 [-0.04; 0.25] 0.170
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Cough, n (%)	1 (3.2)	3 (10.7)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				1.43 [0.15; 18.54] 1.000	1.39 [0.25; 7.68] 1.000	0.03 [-0.12; 0.18] 0.700
Mild, n (%)	1 (3.2)	3 (10.7)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				1.43 [0.15; 18.54] 1.000	1.39 [0.25; 7.68] 1.000	0.03 [-0.12; 0.18] 0.700
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
General disorders and administration site conditions, n (%)	7 (22.6)	6 (21.4)	6 (23.1)			
SEC low vs. ETA				0.97 [0.24; 4.13] 1.000	0.98 [0.38; 2.55] 1.000	-0.00 [-0.22; 0.21] 0.965
SEC high vs. ETA				0.91 [0.21; 4.03] 1.000	0.93 [0.34; 2.52] 1.000	-0.02 [-0.24; 0.21] 0.884
Mild, n (%)	7 (22.6)	5 (17.9)	5 (19.2)			
SEC low vs. ETA				1.22 [0.28; 5.66] 1.000	1.17 [0.42; 3.26] 1.000	0.03 [-0.18; 0.24] 0.756
SEC high vs. ETA				0.91 [0.18; 4.60] 1.000	0.93 [0.30; 2.84] 1.000	-0.01 [-0.22; 0.19] 0.897
Moderate, n (%)	0 (0.0)	1 (3.6)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [0.01; 75.55] 1.000	0.93 [0.06; 14.10] 1.000	-0.00 [-0.10; 0.10] 0.957
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Investigations, n (%)	4 (12.9)	1 (3.6)	5 (19.2)			
SEC low vs. ETA				0.63 [0.11; 3.32] 0.770	0.67 [0.20; 2.24] 0.718	-0.06 [-0.26; 0.13] 0.518
SEC high vs. ETA				0.16 [<0.01; 1.59] 0.160	0.19 [0.02; 1.49] 0.095	-0.16 [-0.32; 0.01] 0.065
Mild, n (%)	4 (12.9)	0 (0.0)	3 (11.5)			
SEC low vs. ETA				1.13 [0.17; 8.55] 1.000	1.12 [0.27; 4.55] 1.000	0.01 [-0.16; 0.18] 0.875
SEC high vs. ETA				0.23 [<0.01; 2.19] 0.210	0.13 [0.01; 2.46] 0.105	-0.12 [-0.24; 0.01] 0.066

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	2 (6.5)	1 (3.6)	3 (11.5)			
SEC low vs. ETA				0.53 [0.04; 5.08] 0.830	0.56 [0.10; 3.10] 0.651	-0.05 [-0.20; 0.10] 0.507
SEC high vs. ETA				0.29 [<0.01; 3.90] 0.555	0.31 [0.03; 2.79] 0.342	-0.08 [-0.22; 0.06] 0.267
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Nervous system disorders, n (%)	4 (12.9)	5 (17.9)	3 (11.5)			
SEC low vs. ETA				1.13 [0.17; 8.55] 1.000	1.12 [0.27; 4.55] 1.000	0.01 [-0.16; 0.18] 0.875
SEC high vs. ETA				1.65 [0.28; 11.89] 0.792	1.55 [0.41; 5.84] 0.706	0.06 [-0.12; 0.25] 0.509
Mild, n (%)	4 (12.9)	5 (17.9)	2 (7.7)			
SEC low vs. ETA				1.76 [0.23; 21.10] 0.848	1.68 [0.33; 8.44] 0.678	0.05 [-0.10; 0.21] 0.513
SEC high vs. ETA				2.56 [0.37; 29.49] 0.485	2.32 [0.49; 10.94] 0.423	0.10 [-0.07; 0.28] 0.255
Moderate, n (%)	0 (0.0)	0 (0.0)	2 (7.7)			
SEC low vs. ETA				0.34 [<0.01; 4.43] 0.407	0.17 [0.01; 3.37] 0.204	-0.08 [-0.18; 0.03] 0.141
SEC high vs. ETA				0.37 [<0.01; 4.91] 0.454	0.19 [0.01; 3.71] 0.227	-0.08 [-0.18; 0.03] 0.141
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Headache, n (%)	4 (12.9)	5 (17.9)	3 (11.5)			
SEC low vs. ETA				1.13 [0.17; 8.55] 1.000	1.12 [0.27; 4.55] 1.000	0.01 [-0.16; 0.18] 0.875
SEC high vs. ETA				1.65 [0.28; 11.89] 0.792	1.55 [0.41; 5.84] 0.706	0.06 [-0.12; 0.25] 0.509

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	4 (12.9)	5 (17.9)	2 (7.7)			
SEC low vs. ETA				1.76 [0.23; 21.10] 0.848	1.68 [0.33; 8.44] 0.678	0.05 [-0.10; 0.21] 0.513
SEC high vs. ETA				2.56 [0.37; 29.49] 0.485	2.32 [0.49; 10.94] 0.423	0.10 [-0.07; 0.28] 0.255
Moderate, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Blood and lymphatic system disorders, n (%)	4 (12.9)	2 (7.1)	1 (3.8)			
SEC low vs. ETA				3.63 [0.33; 189.55] 0.472	3.35 [0.40; 28.19] 0.362	0.09 [-0.05; 0.23] 0.202
SEC high vs. ETA				1.90 [0.09; 117.92] 1.000	1.86 [0.18; 19.29] 1.000	0.03 [-0.09; 0.15] 0.592
Mild, n (%)	2 (6.5)	2 (7.1)	0 (0.0)			
SEC low vs. ETA				2.07 [0.16; >999.99] 0.583	4.22 [0.21; 84.14] 0.495	0.06 [-0.02; 0.15] 0.144
SEC high vs. ETA				2.30 [0.18; >999.99] 0.528	4.66 [0.23; 92.65] 0.491	0.07 [-0.02; 0.17] 0.142
Moderate, n (%)	2 (6.5)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				1.71 [0.08; 105.73] 1.000	1.68 [0.16; 17.47] 1.000	0.03 [-0.09; 0.14] 0.654
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	1 (3.6)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.93 [0.02; >999.99] 1.000	2.79 [0.12; 65.67] 1.000	0.04 [-0.03; 0.10] 0.309
Musculoskeletal and connective tissue disorders, n (%)	0 (0.0)	2 (7.1)	4 (15.4)			
SEC low vs. ETA				0.14 [<0.01; 1.20] 0.076	0.09 [0.01; 1.66] 0.038	-0.15 [-0.29; -0.02] 0.030
SEC high vs. ETA				0.43 [0.04; 3.33] 0.598	0.46 [0.09; 2.33] 0.413	-0.08 [-0.25; 0.09] 0.337
Mild, n (%)	0 (0.0)	1 (3.6)	3 (11.5)			
SEC low vs. ETA				0.20 [<0.01; 1.97] 0.178	0.12 [0.01; 2.23] 0.089	-0.12 [-0.24; 0.01] 0.066
SEC high vs. ETA				0.29 [<0.01; 3.90] 0.555	0.31 [0.03; 2.79] 0.342	-0.08 [-0.22; 0.06] 0.267
Moderate, n (%)	0 (0.0)	1 (3.6)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [0.01; 75.55] 1.000	0.93 [0.06; 14.10] 1.000	-0.00 [-0.10; 0.10] 0.957
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Reproductive system and breast disorders, n (%)	3 (9.7)	4 (14.3)	3 (11.5)			
SEC low vs. ETA				0.82 [0.10; 6.76] 1.000	0.84 [0.18; 3.81] 1.000	-0.02 [-0.18; 0.14] 0.821
SEC high vs. ETA				1.27 [0.19; 9.65] 1.000	1.24 [0.31; 5.01] 1.000	0.03 [-0.15; 0.21] 0.763

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	3 (9.7)	4 (14.3)	3 (11.5)			
SEC low vs. ETA				0.82 [0.10; 6.76] 1.000	0.84 [0.18; 3.81] 1.000	-0.02 [-0.18; 0.14] 0.821
SEC high vs. ETA				1.27 [0.19; 9.65] 1.000	1.24 [0.31; 5.01] 1.000	0.03 [-0.15; 0.21] 0.763
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Dysmenorrhoea, n (%)	1 (3.2)	3 (10.7)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				1.43 [0.15; 18.54] 1.000	1.39 [0.25; 7.68] 1.000	0.03 [-0.12; 0.18] 0.700
Mild, n (%)	1 (3.2)	3 (10.7)	2 (7.7)			
SEC low vs. ETA				0.41 [<0.01; 8.24] 0.866	0.42 [0.04; 4.37] 0.587	-0.04 [-0.16; 0.08] 0.465
SEC high vs. ETA				1.43 [0.15; 18.54] 1.000	1.39 [0.25; 7.68] 1.000	0.03 [-0.12; 0.18] 0.700
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Injury, poisoning and procedural complications, n (%)	3 (9.7)	3 (10.7)	1 (3.8)			
SEC low vs. ETA				2.64 [0.20; 146.14] 0.751	2.52 [0.28; 22.76] 0.617	0.06 [-0.07; 0.19] 0.371
SEC high vs. ETA				2.94 [0.22; 163.67] 0.668	2.79 [0.31; 25.12] 0.612	0.07 [-0.07; 0.21] 0.323

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Mild, n (%)	3 (9.7)	3 (10.7)	0 (0.0)			
SEC low vs. ETA				3.40 [0.35; >999.99] 0.307	5.91 [0.32; 109.36] 0.242	0.10 [-0.01; 0.20] 0.068
SEC high vs. ETA				3.79 [0.39; >999.99] 0.264	6.52 [0.35; 120.42] 0.237	0.11 [-0.01; 0.22] 0.067
Moderate, n (%)	0 (0.0)	1 (3.6)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [0.01; 75.55] 1.000	0.93 [0.06; 14.10] 1.000	-0.00 [-0.10; 0.10] 0.957
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.1.3 Serious Adverse Events by SOC, PT and Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
Any SAE, n (%)	3 (9.7)	3 (10.7)	5 (19.2)			
SEC low vs. ETA				0.46 [0.06; 2.65] 0.514	0.50 [0.13; 1.91] 0.448	-0.10 [-0.28; 0.09] 0.308
SEC high vs. ETA				0.51 [0.07; 2.98] 0.620	0.56 [0.15; 2.10] 0.460	-0.09 [-0.28; 0.10] 0.379
Mild, n (%)	1 (3.2)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.84 [0.02; >999.99] 1.000	2.53 [0.11; 59.63] 1.000	0.03 [-0.03; 0.09] 0.309
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	1 (3.2)	1 (3.6)	3 (11.5)			
SEC low vs. ETA				0.26 [<0.01; 3.50] 0.484	0.28 [0.03; 2.53] 0.322	-0.08 [-0.22; 0.05] 0.237
SEC high vs. ETA				0.29 [<0.01; 3.90] 0.555	0.31 [0.03; 2.79] 0.342	-0.08 [-0.22; 0.06] 0.267
Severe, n (%)	1 (3.2)	2 (7.1)	3 (11.5)			
SEC low vs. ETA				0.26 [<0.01; 3.50] 0.484	0.28 [0.03; 2.53] 0.322	-0.08 [-0.22; 0.05] 0.237
SEC high vs. ETA				0.60 [0.05; 5.68] 0.928	0.62 [0.11; 3.41] 0.663	-0.04 [-0.20; 0.11] 0.580
Gastrointestinal disorders, n (%)	0 (0.0)	0 (0.0)	3 (11.5)			
SEC low vs. ETA				0.20 [<0.01; 1.97] 0.178	0.12 [0.01; 2.23] 0.089	-0.12 [-0.24; 0.01] 0.066
SEC high vs. ETA				0.23 [<0.01; 2.19] 0.210	0.13 [0.01; 2.46] 0.105	-0.12 [-0.24; 0.01] 0.066
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	0 (0.0)	0 (0.0)	2 (7.7)			
SEC low vs. ETA				0.34 [<0.01; 4.43] 0.407	0.17 [0.01; 3.37] 0.204	-0.08 [-0.18; 0.03] 0.141
SEC high vs. ETA				0.37 [<0.01; 4.91] 0.454	0.19 [0.01; 3.71] 0.227	-0.08 [-0.18; 0.03] 0.141
Severe, n (%)	0 (0.0)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [<0.01; 32.71] 0.912	0.28 [0.01; 6.63] 0.456	-0.04 [-0.11; 0.04] 0.308
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S1.4 Any AE Leading to Study Discontinuation

There are no data meeting the display criteria for this table.

S1.5 Any AE Leading to Study Drug Discontinuation by SOC and PT, Frequencies (SAF)

	Treatment Groups		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**
N'	31	28	26
Investigations, n (%)	0 (0.0)	0 (0.0)	1 (3.8)
Hepatic enzyme increased, n (%)	0 (0.0)	0 (0.0)	1 (3.8)
Psychiatric disorders, n (%)	1 (3.2)	0 (0.0)	0 (0.0)
Behaviour disorder, n (%)	1 (3.2)	0 (0.0)	0 (0.0)
Major depression, n (%)	1 (3.2)	0 (0.0)	0 (0.0)
Mental disorder, n (%)	1 (3.2)	0 (0.0)	0 (0.0)
Suicidal ideation, n (%)	1 (3.2)	0 (0.0)	0 (0.0)

N': Number of patients in the analysis
n (%): Number and percentage of patients with event

S.1.6 Adverse Events of Special Interest by Severity, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
Infections and infestations (SOC), n (%)	21 (67.7)	21 (75.0)	19 (73.1)			
SEC low vs. ETA				0.78 [0.21; 2.80] 0.886	0.93 [0.66; 1.30] 0.774	-0.05 [-0.29; 0.18] 0.659
SEC high vs. ETA				1.10 [0.27; 4.46] 1.000	1.03 [0.75; 1.41] 1.000	0.02 [-0.21; 0.25] 0.872
Mild, n (%)	19 (61.3)	20 (71.4)	17 (65.4)			
SEC low vs. ETA				0.84 [0.25; 2.82] 0.967	0.94 [0.63; 1.39] 0.789	-0.04 [-0.29; 0.21] 0.749
SEC high vs. ETA				1.32 [0.36; 4.91] 0.853	1.09 [0.76; 1.57] 0.771	0.06 [-0.19; 0.31] 0.633
Moderate, n (%)	8 (25.8)	9 (32.1)	8 (30.8)			
SEC low vs. ETA				0.79 [0.21; 2.93] 0.902	0.84 [0.37; 1.92] 0.771	-0.05 [-0.28; 0.19] 0.679
SEC high vs. ETA				1.06 [0.29; 3.96] 1.000	1.04 [0.47; 2.30] 1.000	0.01 [-0.23; 0.26] 0.913
Severe, n (%)	1 (3.2)	2 (7.1)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				1.90 [0.09; 117.92] 1.000	1.86 [0.18; 19.29] 1.000	0.03 [-0.09; 0.15] 0.592
Serious, n (%)	1 (3.2)	1 (3.6)	0 (0.0)			
SEC low vs. ETA				0.84 [0.02; >999.99] 1.000	2.53 [0.11; 59.63] 1.000	0.03 [-0.03; 0.09] 0.309
SEC high vs. ETA				0.93 [0.02; >999.99] 1.000	2.79 [0.12; 65.67] 1.000	0.04 [-0.03; 0.10] 0.309

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Hypersensitivity (SMQ) (narrow), n (%)	3 (9.7)	7 (25.0)	3 (11.5)			
SEC low vs. ETA				0.82 [0.10; 6.76] 1.000	0.84 [0.18; 3.81] 1.000	-0.02 [-0.18; 0.14] 0.821
SEC high vs. ETA				2.51 [0.49; 17.02] 0.358	2.17 [0.63; 7.51] 0.298	0.13 [-0.07; 0.34] 0.192
Mild, n (%)	3 (9.7)	4 (14.3)	3 (11.5)			
SEC low vs. ETA				0.82 [0.10; 6.76] 1.000	0.84 [0.18; 3.81] 1.000	-0.02 [-0.18; 0.14] 0.821
SEC high vs. ETA				1.27 [0.19; 9.65] 1.000	1.24 [0.31; 5.01] 1.000	0.03 [-0.15; 0.21] 0.763
Moderate, n (%)	0 (0.0)	3 (10.7)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				3.79 [0.39; >999.99] 0.264	6.52 [0.35; 120.42] 0.237	0.11 [-0.01; 0.22] 0.067
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Neutropenia (NMQ) (narrow), n (%)	2 (6.5)	1 (3.6)	1 (3.8)			
SEC low vs. ETA				1.71 [0.08; 105.73] 1.000	1.68 [0.16; 17.47] 1.000	0.03 [-0.09; 0.14] 0.654
SEC high vs. ETA				0.93 [0.01; 75.55] 1.000	0.93 [0.06; 14.10] 1.000	-0.00 [-0.10; 0.10] 0.957
Mild, n (%)	1 (3.2)	1 (3.6)	0 (0.0)			
SEC low vs. ETA				0.84 [0.02; >999.99] 1.000	2.53 [0.11; 59.63] 1.000	0.03 [-0.03; 0.09] 0.309
SEC high vs. ETA				0.93 [0.02; >999.99] 1.000	2.79 [0.12; 65.67] 1.000	0.04 [-0.03; 0.10] 0.309

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	1 (3.2)	0 (0.0)	1 (3.8)			
SEC low vs. ETA				0.84 [0.01; 68.00] 1.000	0.84 [0.06; 12.76] 1.000	-0.01 [-0.10; 0.09] 0.900
SEC high vs. ETA				0.93 [<0.01; 36.21] 0.963	0.31 [0.01; 7.30] 0.481	-0.04 [-0.11; 0.04] 0.308
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT), n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Mild, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Severe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Serious, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

Die Diskrepanz in der Häufigkeit der Ereignisse in der SOC Infections and Investigations im Vergleich zu S.1.2 erklärt sich folgendermaßen: In S.1.2. (UE nach SOC und PT) wird die Primary SOC verwendet wird, während in S.1.6. auch Events zur SOC Infections and infestations zugeordnet werden, die zwar auch zu dieser SOC gehören, aber primär einer anderen SOC zugeordnet sind. Konkret handelt es sich dabei um das AE ‚Virus warts' in der Gruppe SEC high (PT: Skin papilloma, Primary SOC: Neoplasms benign, malignant and unspecified, Secondary SOCs: Skin and subcutaneous tissue disorders / Infections and infestations).

S.1.7 Tanner Stage, Binary Analysis (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
N'	**31**	**28**	**26**			
n (%)	27 (87.1)	21 (75.0)	22 (84.6)			
SEC low vs. ETA				1.22 [0.20; 7.38] 1.000	1.03 [0.83; 1.27] 1.000	0.02 [-0.16; 0.21] 0.789
SEC high vs. ETA				0.55 [0.10; 2.55] 0.593	0.89 [0.68; 1.16] 0.505	-0.10 [-0.31; 0.12] 0.374
Pubertal at Week 52						
N'	**29**	**27**	**23**			
n (%)	26 (89.7)	21 (77.8)	21 (91.3)			
SEC low vs. ETA				0.83 [0.06; 7.95] 1.000	0.98 [0.82; 1.17] 1.000	-0.02 [-0.18; 0.14] 0.840
SEC high vs. ETA				0.34 [0.03; 2.19] 0.363	0.85 [0.67; 1.08] 0.261	-0.14 [-0.33; 0.06] 0.173

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

OR (with CI and p-value) from exact logistic regression model with treatment as predictor.
RR and RD calculated directly (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

OR, RR and RD are N.E. if the incidence of events is zero or 100% in both involved treatment groups.

S.2.1 Adverse Events, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Age < 12 years	8	6	6			
N' Age ≥ 12 years	23	22	20			
Any AE						
Interaction test:	p=0.680					
Age < 12 years, n (%)	7 (87.5)	5 (83.3)	5 (83.3)			
SEC low vs. ETA				1.37 [0.01; 125.38] 1.000	1.05 [0.67; 1.64] 1.000	0.04 [-0.33; 0.42] 0.828
SEC high vs. ETA				1.00 [0.01; 94.01] 1.000	1.00 [0.60; 1.66] 1.000	0.00 [-0.42; 0.42] 1.000
Age ≥ 12 years, n (%)	18 (78.3)	19 (86.4)	19 (95.0)			
SEC low vs. ETA				0.20 [<0.01; 2.00] 0.254	0.82 [0.65; 1.04] 0.192	-0.17 [-0.36; 0.03] 0.090
SEC high vs. ETA				0.34 [<0.01; 4.70] 0.681	0.91 [0.75; 1.10] 0.608	-0.09 [-0.26; 0.09] 0.326
Any SAE						
Interaction test:	p=0.672					
Age < 12 years, n (%)	0 (0.0)	1 (16.7)	1 (16.7)			
SEC low vs. ETA				0.75 [<0.01; 29.25] 0.857	0.26 [0.01; 5.44] 0.429	-0.17 [-0.46; 0.13] 0.273
SEC high vs. ETA				1.00 [0.01; 94.01] 1.000	1.00 [0.08; 12.56] 1.000	0.00 [-0.42; 0.42] 1.000
Age ≥ 12 years, n (%)	3 (13.0)	2 (9.1)	4 (20.0)			
SEC low vs. ETA				0.61 [0.08; 4.17] 0.836	0.65 [0.17; 2.57] 0.687	-0.07 [-0.29; 0.15] 0.541
SEC high vs. ETA				0.41 [0.03; 3.28] 0.572	0.45 [0.09; 2.22] 0.400	-0.11 [-0.32; 0.10] 0.314

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=1.000					
Age < 12 years, n (%)	0 (0.0)	1 (16.7)	1 (16.7)			
SEC low vs. ETA				0.75 [<0.01; 29.25] 0.857	0.26 [0.01; 5.44] 0.429	-0.17 [-0.46; 0.13] 0.273
SEC high vs. ETA				1.00 [0.01; 94.01] 1.000	1.00 [0.08; 12.56] 1.000	0.00 [-0.42; 0.42] 1.000
Age ≥ 12 years, n (%)	1 (4.3)	1 (4.5)	3 (15.0)			
SEC low vs. ETA				0.27 [<0.01; 3.64] 0.503	0.29 [0.03; 2.57] 0.323	-0.11 [-0.28; 0.07] 0.239
SEC high vs. ETA				0.28 [<0.01; 3.82] 0.535	0.30 [0.03; 2.68] 0.333	-0.10 [-0.28; 0.07] 0.253
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Age ≥ 12 years, n (%)	1 (4.3)	0 (0.0)	1 (5.0)			
SEC low vs. ETA				0.87 [0.01; 71.32] 1.000	0.87 [0.06; 13.02] 1.000	-0.01 [-0.13; 0.12] 0.920
SEC high vs. ETA				0.91 [<0.01; 35.45] 0.952	0.30 [0.01; 7.07] 0.476	-0.05 [-0.15; 0.05] 0.305

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.2 Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Age < 12 years	8	6	6			
N' Age ≥ 12 years	23	22	20			
Musculoskeletal and connective tissue disorders						
Interaction test:	p=1.000					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	1 (16.7)			
SEC low vs. ETA				0.75 [<0.01; 29.25] 0.857	0.26 [0.01; 5.44] 0.429	-0.17 [-0.46; 0.13] 0.273
SEC high vs. ETA				1.00 [<0.01; 39.00] 1.000	0.33 [0.02; 6.86] 1.000	-0.17 [-0.46; 0.13] 0.273
Age ≥ 12 years, n (%)	0 (0.0)	2 (9.1)	3 (15.0)			
SEC low vs. ETA				0.21 [<0.01; 2.03] 0.185	0.13 [0.01; 2.28] 0.092	-0.15 [-0.31; 0.01] 0.060
SEC high vs. ETA				0.57 [0.04; 5.64] 0.906	0.61 [0.11; 3.26] 0.656	-0.06 [-0.26; 0.14] 0.557

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant ($p < 0.05$ in Fisher's exact test for RR).
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.3 Serious Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.4 Severe Adverse Events by SOC and PT, Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

S.2.5 Adverse Events of Special Interest, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Age < 12 years	8	6	6			
N' Age ≥ 12 years	23	22	20			
Infections and infestations (SOC)						
Interaction test:	p=0.534					
Age < 12 years, n (%)	5 (62.5)	5 (83.3)	3 (50.0)			
SEC low vs. ETA				1.61 [0.12; 22.59] 1.000	1.25 [0.48; 3.28] 1.000	0.13 [-0.40; 0.65] 0.639
SEC high vs. ETA				4.34 [0.22; 313.87] 0.545	1.67 [0.69; 4.00] 0.545	0.33 [-0.17; 0.83] 0.190
Age ≥ 12 years, n (%)	16 (69.6)	16 (72.7)	16 (80.0)			
SEC low vs. ETA				0.58 [0.10; 2.83] 0.670	0.87 [0.61; 1.23] 0.501	-0.10 [-0.36; 0.15] 0.426
SEC high vs. ETA				0.67 [0.12; 3.49] 0.853	0.91 [0.65; 1.27] 0.723	-0.07 [-0.33; 0.18] 0.577
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.691					
Age < 12 years, n (%)	0 (0.0)	1 (16.7)	1 (16.7)			
SEC low vs. ETA				0.75 [<0.01; 29.25] 0.857	0.26 [0.01; 5.44] 0.429	-0.17 [-0.46; 0.13] 0.273
SEC high vs. ETA				1.00 [0.01; 94.01] 1.000	1.00 [0.08; 12.56] 1.000	0.00 [-0.42; 0.42] 1.000
Age ≥ 12 years, n (%)	3 (13.0)	6 (27.3)	2 (10.0)			
SEC low vs. ETA				1.34 [0.14; 17.77] 1.000	1.30 [0.24; 7.04] 1.000	0.03 [-0.16; 0.22] 0.754
SEC high vs. ETA				3.28 [0.49; 37.77] 0.303	2.73 [0.62; 12.00] 0.243	0.17 [-0.06; 0.40] 0.137

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.246					
Age < 12 years, n (%)	2 (25.0)	1 (16.7)	0 (0.0)			
SEC low vs. ETA				1.98 [0.14; >999.99] 0.615	3.89 [0.22; 68.68] 0.473	0.25 [-0.05; 0.55] 0.102
SEC high vs. ETA				1.00 [0.03; >999.99] 1.000	3.00 [0.15; 61.74] 1.000	0.17 [-0.13; 0.46] 0.273
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	1 (5.0)			
SEC low vs. ETA				0.87 [<0.01; 33.91] 0.930	0.29 [0.01; 6.78] 0.465	-0.05 [-0.15; 0.05] 0.305
SEC high vs. ETA				0.91 [<0.01; 35.45] 0.952	0.30 [0.01; 7.07] 0.476	-0.05 [-0.15; 0.05] 0.305
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Age < 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Age ≥ 12 years, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.2.6 Tanner Stage, Binary Analysis by Age (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=1.000**					
Age < 12 years, N / N'	**8 / 8**	**6 / 6**	**6 / 6**			
n (%)	4 (50.0)	1 (16.7)	3 (50.0)			
SEC low vs. ETA				1.00 [0.08; 13.03] 1.000	1.00 [0.35; 2.88] 1.000	0.00 [-0.53; 0.53] 1.000
SEC high vs. ETA				0.23 [<0.01; 4.50] 0.545	0.33 [0.05; 2.37] 0.545	-0.33 [-0.83; 0.17] 0.190
Age ≥ 12 years, N / N'	**23 / 23**	**22 / 22**	**20 / 20**			
n (%)	23 (100.0)	20 (90.9)	19 (95.0)			
SEC low vs. ETA				1.15 [0.03; N.E.] 0.930	1.05 [0.95; 1.16] 0.465	0.05 [-0.05; 0.15] 0.305
SEC high vs. ETA				0.53 [<0.01; 11.06] 1.000	0.96 [0.81; 1.13] 1.000	-0.04 [-0.19; 0.11] 0.601
Pubertal at Week 52						
Interaction Test	**p=1.000**					
Age < 12 years, N / N'	**8 / 8**	**6 / 6**	**6 / 4**			
n (%)	5 (62.5)	1 (16.7)	2 (50.0)			
SEC low vs. ETA				1.60 [0.08; 34.55] 1.000	1.25 [0.41; 3.82] 1.000	0.13 [-0.47; 0.72] 0.680
SEC high vs. ETA				0.24 [<0.01; 7.08] 0.667	0.33 [0.04; 2.56] 0.500	-0.33 [-0.91; 0.24] 0.255
Age ≥ 12 years, N / N'	**23 / 21**	**22 / 21**	**20 / 19**			
n (%)	21 (100.0)	20 (95.2)	19 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.11 [N.E.; 43.11] 1.000	0.95 [0.87; 1.05] 1.000	-0.05 [-0.14; 0.04] 0.306

Treatment Groups			Comparison		
SEC low (N=31)	SEC high (N=28)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.1 Adverse Events, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Male	9	13	10			
N' Female	22	15	16			
Any AE						
Interaction test:	p=0.021					
Male, n (%)	9 (100.0)	9 (69.2)	9 (90.0)			
SEC low vs. ETA				0.90 [0.02; >999.99] 1.000	1.11 [0.90; 1.37] 1.000	0.10 [-0.09; 0.29] 0.292
SEC high vs. ETA				0.26 [<0.01; 3.40] 0.501	0.77 [0.51; 1.17] 0.339	-0.21 [-0.52; 0.10] 0.192
Female, n (%)	16 (72.7)	15 (100.0)	15 (93.8)			
SEC low vs. ETA				0.18 [<0.01; 1.81] 0.216	0.78 [0.58; 1.03] 0.203	-0.21 [-0.43; 0.01] 0.062
SEC high vs. ETA				0.94 [0.02; >999.99] 1.000	1.07 [0.94; 1.21] 1.000	0.06 [-0.06; 0.18] 0.302
Any SAE						
Interaction test:	p=0.511					
Male, n (%)	0 (0.0)	1 (7.7)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				0.77 [0.02; >999.99] 1.000	2.36 [0.11; 52.41] 1.000	0.08 [-0.07; 0.22] 0.298
Female, n (%)	3 (13.6)	2 (13.3)	5 (31.3)			
SEC low vs. ETA				0.36 [0.05; 2.25] 0.362	0.44 [0.12; 1.57] 0.243	-0.18 [-0.44; 0.09] 0.199
SEC high vs. ETA				0.35 [0.03; 2.68] 0.449	0.43 [0.10; 1.88] 0.394	-0.18 [-0.46; 0.11] 0.218

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=1.000					
Male, n (%)	0 (0.0)	0 (0.0)	1 (10.0)			
SEC low vs. ETA				1.11 [<0.01; 43.33] 1.000	0.37 [0.02; 8.01] 1.000	-0.10 [-0.29; 0.09] 0.292
SEC high vs. ETA				0.77 [<0.01; 30.00] 0.870	0.26 [0.01; 5.82] 0.435	-0.10 [-0.29; 0.09] 0.292
Female, n (%)	1 (4.5)	2 (13.3)	3 (18.8)			
SEC low vs. ETA				0.22 [<0.01; 3.00] 0.383	0.24 [0.03; 2.12] 0.291	-0.14 [-0.35; 0.07] 0.185
SEC high vs. ETA				0.68 [0.05; 6.96] 1.000	0.71 [0.14; 3.68] 1.000	-0.05 [-0.31; 0.20] 0.680
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=1.000					
Male, n (%)	0 (0.0)	0 (0.0)	1 (10.0)			
SEC low vs. ETA				1.11 [<0.01; 43.33] 1.000	0.37 [0.02; 8.01] 1.000	-0.10 [-0.29; 0.09] 0.292
SEC high vs. ETA				0.77 [<0.01; 30.00] 0.870	0.26 [0.01; 5.82] 0.435	-0.10 [-0.29; 0.09] 0.292

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Female, n (%)	1 (4.5)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.22 [0.10; 51.16] 1.000	0.05 [-0.04; 0.13] 0.306
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.2 Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Male	9	13	10			
N' Female	22	15	16			
Musculoskeletal and connective tissue disorders						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	2 (13.3)	4 (25.0)			
SEC low vs. ETA				0.11 [<0.01; 0.99] 0.049	0.08 [0.00; 1.43] 0.025	-0.25 [-0.46; -0.04] 0.021
SEC high vs. ETA				0.47 [0.04; 4.02] 0.719	0.53 [0.11; 2.50] 0.654	-0.12 [-0.39; 0.16] 0.403

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant ($p < 0.05$ in Fisher's exact test for RR).
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.3 Serious Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.4 Severe Adverse Events by SOC and PT, Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

S.3.5 Adverse Events of Special Interest, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Male	9	13	10			
N' Female	22	15	16			
Infections and infestations (SOC)						
Interaction test:	p=0.041					
Male, n (%)	8 (88.9)	8 (61.5)	9 (90.0)			
SEC low vs. ETA				0.89 [0.01; 78.40] 1.000	0.99 [0.72; 1.35] 1.000	-0.01 [-0.29; 0.27] 0.937
SEC high vs. ETA				0.19 [<0.01; 2.25] 0.289	0.68 [0.42; 1.10] 0.179	-0.28 [-0.61; 0.04] 0.084
Female, n (%)	13 (59.1)	13 (86.7)	10 (62.5)			
SEC low vs. ETA				0.87 [0.19; 3.90] 1.000	0.95 [0.57; 1.58] 1.000	-0.03 [-0.35; 0.28] 0.831
SEC high vs. ETA				3.73 [0.52; 45.57] 0.260	1.39 [0.90; 2.13] 0.220	0.24 [-0.05; 0.53] 0.106
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=1.000					
Male, n (%)	0 (0.0)	2 (15.4)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				1.96 [0.14; >999.99] 0.617	3.93 [0.21; 73.71] 0.486	0.15 [-0.04; 0.35] 0.124
Female, n (%)	3 (13.6)	5 (33.3)	3 (18.8)			
SEC low vs. ETA				0.69 [0.08; 5.99] 1.000	0.73 [0.17; 3.15] 0.682	-0.05 [-0.29; 0.19] 0.675
SEC high vs. ETA				2.11 [0.32; 17.00] 0.606	1.78 [0.51; 6.18] 0.433	0.15 [-0.16; 0.45] 0.350
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Female, n (%)	2 (9.1)	1 (6.7)	1 (6.3)			
SEC low vs. ETA				1.48 [0.07; 94.31] 1.000	1.45 [0.14; 14.69] 1.000	0.03 [-0.14; 0.20] 0.742
SEC high vs. ETA				1.07 [0.01; 89.64] 1.000	1.07 [0.07; 15.57] 1.000	0.00 [-0.17; 0.18] 0.962
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Male, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Female, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.3.6 Tanner Stage, Binary Analysis by Gender (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=1.000**					
Male, N / N'	**9 / 9**	**13 / 13**	**10 / 10**			
n (%)	8 (88.9)	9 (69.2)	8 (80.0)			
SEC low vs. ETA				1.93 [0.08; 132.51] 1.000	1.11 [0.75; 1.64] 1.000	0.09 [-0.23; 0.41] 0.588
SEC high vs. ETA				0.58 [0.04; 5.39] 0.926	0.87 [0.54; 1.39] 0.660	-0.11 [-0.46; 0.25] 0.550
Female, N / N'	**22 / 22**	**15 / 15**	**16 / 16**			
n (%)	19 (86.4)	12 (80.0)	14 (87.5)			
SEC low vs. ETA				0.91 [0.07; 9.07] 1.000	0.99 [0.77; 1.27] 1.000	-0.01 [-0.23; 0.21] 0.918
SEC high vs. ETA				0.58 [0.04; 5.99] 0.935	0.91 [0.67; 1.25] 0.654	-0.07 [-0.33; 0.18] 0.571
Pubertal at Week 52						
Interaction Test	**p=0.518**					
Male, N / N'	**9 / 8**	**13 / 13**	**10 / 8**			
n (%)	8 (100.0)	10 (76.9)	7 (87.5)			
SEC low vs. ETA				1.00 [0.03; N.E.] 1.000	1.14 [0.88; 1.49] 1.000	0.13 [-0.10; 0.35] 0.285
SEC high vs. ETA				0.49 [<0.01; 7.73] 1.000	0.88 [0.59; 1.31] 1.000	-0.11 [-0.43; 0.22] 0.522
Female, N / N'	**22 / 21**	**15 / 14**	**16 / 15**			
n (%)	18 (85.7)	11 (78.6)	14 (93.3)			
SEC low vs. ETA				0.44 [<0.01; 6.15] 0.881	0.92 [0.74; 1.15] 0.626	-0.08 [-0.27; 0.12] 0.446
SEC high vs. ETA				0.27 [<0.01; 3.96] 0.544	0.84 [0.62; 1.14] 0.330	-0.15 [-0.40; 0.10] 0.246

Treatment Groups			Comparison		
SEC low (N=31)	SEC high (N=28)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.1 Adverse Events, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Baseline PASI ≤ Median	16	12	13			
N' Baseline PASI > Median	15	16	13			
Any AE						
Interaction test:	p=0.067					
Baseline PASI ≤ Median, n (%)	15 (93.8)	9 (75.0)	12 (92.3)			
SEC low vs. ETA				1.24 [0.01; 104.57] 1.000	1.02 [0.83; 1.24] 1.000	0.01 [-0.17; 0.20] 0.880
SEC high vs. ETA				0.26 [<0.01; 3.93] 0.530	0.81 [0.57; 1.17] 0.322	-0.17 [-0.46; 0.11] 0.233
Baseline PASI > Median, n (%)	10 (66.7)	15 (93.8)	12 (92.3)			
SEC low vs. ETA				0.18 [<0.01; 1.97] 0.234	0.72 [0.49; 1.07] 0.173	-0.26 [-0.54; 0.02] 0.072
SEC high vs. ETA				1.24 [0.01; 104.57] 1.000	1.02 [0.83; 1.24] 1.000	0.01 [-0.17; 0.20] 0.880
Any SAE						
Interaction test:	p=0.741					
Baseline PASI ≤ Median, n (%)	2 (12.5)	2 (16.7)	2 (15.4)			
SEC low vs. ETA				0.79 [0.05; 12.58] 1.000	0.81 [0.13; 5.01] 1.000	-0.03 [-0.28; 0.23] 0.824
SEC high vs. ETA				1.10 [0.07; 17.83] 1.000	1.08 [0.18; 6.53] 1.000	0.01 [-0.28; 0.30] 0.930
Baseline PASI > Median, n (%)	1 (6.7)	1 (6.3)	3 (23.1)			
SEC low vs. ETA				0.25 [<0.01; 3.65] 0.489	0.29 [0.03; 2.45] 0.311	-0.16 [-0.43; 0.10] 0.219
SEC high vs. ETA				0.23 [<0.01; 3.39] 0.446	0.27 [0.03; 2.31] 0.299	-0.17 [-0.43; 0.09] 0.201

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=0.015					
Baseline PASI ≤ Median, n (%)	1 (6.3)	2 (16.7)	0 (0.0)			
SEC low vs. ETA				0.81 [0.02; >999.99] 1.000	2.47 [0.11; 56.04] 1.000	0.06 [-0.06; 0.18] 0.302
SEC high vs. ETA				2.79 [0.21; >999.99] 0.440	5.38 [0.28; 101.96] 0.220	0.17 [-0.04; 0.38] 0.121
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	4 (30.8)			
SEC low vs. ETA				0.13 [<0.01; 1.16] 0.070	0.10 [0.01; 1.65] 0.035	-0.31 [-0.56; -0.06] 0.016
SEC high vs. ETA				0.12 [<0.01; 1.09] 0.060	0.09 [0.01; 1.56] 0.030	-0.31 [-0.56; -0.06] 0.016
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.484					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	1 (7.7)			
SEC low vs. ETA				0.81 [<0.01; 31.69] 0.897	0.27 [0.01; 6.23] 0.448	-0.08 [-0.22; 0.07] 0.298
SEC high vs. ETA				1.08 [<0.01; 42.25] 1.000	0.36 [0.02; 8.05] 1.000	-0.08 [-0.22; 0.07] 0.298

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Baseline PASI > Median, n (%)	1 (6.7)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.87 [0.02; >999.99] 1.000	2.63 [0.12; 59.40] 1.000	0.07 [-0.06; 0.19] 0.301
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.2 Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Baseline PASI ≤ Median	16	12	13			
N' Baseline PASI > Median	15	16	13			
Musculoskeletal and connective tissue disorders						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	0 (0.0)	1 (8.3)	2 (15.4)			
SEC low vs. ETA				0.32 [<0.01; 4.24] 0.384	0.16 [0.01; 3.16] 0.192	-0.15 [-0.35; 0.04] 0.124
SEC high vs. ETA				0.51 [<0.01; 11.25] 1.000	0.54 [0.06; 5.24] 1.000	-0.07 [-0.32; 0.18] 0.582
Baseline PASI > Median, n (%)	0 (0.0)	1 (6.3)	2 (15.4)			
SEC low vs. ETA				0.34 [<0.01; 4.53] 0.413	0.18 [0.01; 3.35] 0.206	-0.15 [-0.35; 0.04] 0.124
SEC high vs. ETA				0.38 [<0.01; 8.16] 0.840	0.41 [0.04; 4.00] 0.573	-0.09 [-0.32; 0.14] 0.435

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant ($p < 0.05$ in Fisher's exact test for RR).
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.3 Serious Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.4 Severe Adverse Events by SOC and PT, Binary Analysis by Disease Severity (SAF)

There are no data meeting the display criteria for this table.

S.4.5 Adverse Events of Special Interest, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Baseline PASI ≤ Median	16	12	13			
N' Baseline PASI > Median	15	16	13			
Infections and infestations (SOC)						
Interaction test:	p=0.078					
Baseline PASI ≤ Median, n (%)	14 (87.5)	8 (66.7)	10 (76.9)			
SEC low vs. ETA				2.05 [0.20; 28.82] 0.792	1.14 [0.80; 1.62] 0.632	0.11 [-0.17; 0.39] 0.460
SEC high vs. ETA				0.61 [0.07; 4.84] 0.899	0.87 [0.53; 1.43] 0.673	-0.10 [-0.45; 0.25] 0.567
Baseline PASI > Median, n (%)	7 (46.7)	13 (81.3)	9 (69.2)			
SEC low vs. ETA				0.40 [0.06; 2.31] 0.413	0.67 [0.35; 1.29] 0.276	-0.23 [-0.58; 0.13] 0.214
SEC high vs. ETA				1.88 [0.25; 16.17] 0.748	1.17 [0.76; 1.81] 0.667	0.12 [-0.20; 0.44] 0.455
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.241					
Baseline PASI ≤ Median, n (%)	3 (18.8)	4 (33.3)	1 (7.7)			
SEC low vs. ETA				2.68 [0.19; 157.28] 0.766	2.44 [0.29; 20.75] 0.606	0.11 [-0.13; 0.35] 0.366
SEC high vs. ETA				5.59 [0.44; 319.53] 0.272	4.33 [0.56; 33.53] 0.160	0.26 [-0.05; 0.56] 0.098
Baseline PASI > Median, n (%)	0 (0.0)	3 (18.8)	2 (15.4)			
SEC low vs. ETA				0.34 [<0.01; 4.53] 0.413	0.18 [0.01; 3.35] 0.206	-0.15 [-0.35; 0.04] 0.124
SEC high vs. ETA				1.26 [0.12; 17.66] 1.000	1.22 [0.24; 6.24] 1.000	0.03 [-0.24; 0.31] 0.810

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=1.000					
Baseline PASI ≤ Median, n (%)	1 (6.3)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.81 [0.02; >999.99] 1.000	2.47 [0.11; 56.04] 1.000	0.06 [-0.06; 0.18] 0.302
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	1 (6.7)	1 (6.3)	1 (7.7)			
SEC low vs. ETA				0.86 [0.01; 72.83] 1.000	0.87 [0.06; 12.52] 1.000	-0.01 [-0.20; 0.18] 0.917
SEC high vs. ETA				0.81 [<0.01; 67.97] 1.000	0.81 [0.06; 11.77] 1.000	-0.01 [-0.20; 0.17] 0.880
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Baseline PASI ≤ Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Baseline PASI > Median, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.4.6 Tanner Stage, Binary Analysis by Disease Severity (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=0.526**					
Baseline PASI ≤ Median, N / N'	**16 / 16**	**12 / 12**	**13 / 13**			
n (%)	14 (87.5)	8 (66.7)	12 (92.3)			
SEC low vs. ETA				0.59 [<0.01; 12.77] 1.000	0.95 [0.74; 1.21] 1.000	-0.05 [-0.27; 0.17] 0.665
SEC high vs. ETA				0.18 [<0.01; 2.25] 0.272	0.72 [0.47; 1.11] 0.160	-0.26 [-0.56; 0.05] 0.098
Baseline PASI > Median, N / N'	**15 / 15**	**16 / 16**	**13 / 13**			
n (%)	13 (86.7)	13 (81.3)	10 (76.9)			
SEC low vs. ETA				1.90 [0.18; 26.95] 0.856	1.13 [0.79; 1.61] 0.639	0.10 [-0.19; 0.38] 0.505
SEC high vs. ETA				1.29 [0.14; 11.82] 1.000	1.06 [0.72; 1.54] 1.000	0.04 [-0.26; 0.34] 0.776
Pubertal at Week 52						
Interaction Test	**p=0.484**					
Baseline PASI ≤ Median, N / N'	**16 / 15**	**12 / 12**	**13 / 12**			
n (%)	13 (86.7)	9 (75.0)	12 (100.0)			
SEC low vs. ETA				0.49 [N.E.; 6.63] 0.598	0.87 [0.71; 1.06] 0.487	-0.13 [-0.31; 0.04] 0.129
SEC high vs. ETA				0.22 [N.E.; 2.29] 0.217	0.75 [0.54; 1.04] 0.217	-0.25 [-0.50; -0.01] 0.046
Baseline PASI > Median, N / N'	**15 / 14**	**16 / 15**	**13 / 11**			
n (%)	13 (92.9)	12 (80.0)	9 (81.8)			
SEC low vs. ETA				2.77 [0.13; 183.29] 0.813	1.13 [0.83; 1.55] 0.565	0.11 [-0.15; 0.38] 0.414
SEC high vs. ETA				0.89 [0.06; 9.63] 1.000	0.98 [0.67; 1.42] 1.000	-0.02 [-0.32; 0.29] 0.907

	Treatment Groups			Comparison		
	SEC low (N=31)	SEC high (N=28)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.1 Adverse Events, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Europe	21	23	16			
N' Others	10	5	10			
Any AE						
Interaction test:	p=0.129					
Europe, n (%)	19 (90.5)	20 (87.0)	14 (87.5)			
SEC low vs. ETA				1.35 [0.09; 20.70] 1.000	1.03 [0.82; 1.30] 1.000	0.03 [-0.18; 0.23] 0.776
SEC high vs. ETA				0.95 [0.07; 9.51] 1.000	0.99 [0.78; 1.27] 1.000	-0.01 [-0.22; 0.21] 0.960
Others, n (%)	6 (60.0)	4 (80.0)	10 (100.0)			
SEC low vs. ETA				0.14 [<0.01; 1.30] 0.087	0.60 [0.36; 1.00] 0.087	-0.40 [-0.70; -0.10] 0.010
SEC high vs. ETA				0.50 [<0.01; 19.50] 0.667	0.80 [0.52; 1.24] 0.333	-0.20 [-0.55; 0.15] 0.264
Any SAE						
Interaction test:	p=0.643					
Europe, n (%)	2 (9.5)	2 (8.7)	4 (25.0)			
SEC low vs. ETA				0.33 [0.03; 2.68] 0.415	0.38 [0.08; 1.83] 0.371	-0.15 [-0.40; 0.09] 0.219
SEC high vs. ETA				0.30 [0.02; 2.42] 0.349	0.35 [0.07; 1.68] 0.205	-0.16 [-0.40; 0.08] 0.186
Others, n (%)	1 (10.0)	1 (20.0)	1 (10.0)			
SEC low vs. ETA				1.00 [0.01; 87.11] 1.000	1.00 [0.07; 13.87] 1.000	0.00 [-0.26; 0.26] 1.000
SEC high vs. ETA				2.12 [0.02; 195.90] 1.000	2.00 [0.16; 25.76] 1.000	0.10 [-0.30; 0.50] 0.621

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=1.000					
Europe, n (%)	1 (4.8)	1 (4.3)	2 (12.5)			
SEC low vs. ETA				0.36 [<0.01; 7.55] 0.793	0.38 [0.04; 3.84] 0.568	-0.08 [-0.26; 0.11] 0.415
SEC high vs. ETA				0.33 [<0.01; 6.85] 0.727	0.35 [0.03; 3.52] 0.557	-0.08 [-0.26; 0.10] 0.381
Others, n (%)	0 (0.0)	1 (20.0)	2 (20.0)			
SEC low vs. ETA				0.38 [<0.01; 5.23] 0.474	0.20 [0.01; 3.71] 0.474	-0.20 [-0.45; 0.05] 0.114
SEC high vs. ETA				1.00 [0.01; 25.35] 1.000	1.00 [0.12; 8.56] 1.000	0.00 [-0.43; 0.43] 1.000
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=0.432					
Europe, n (%)	0 (0.0)	0 (0.0)	1 (6.3)			
SEC low vs. ETA				0.76 [<0.01; 29.71] 0.865	0.26 [0.01; 5.94] 0.432	-0.06 [-0.18; 0.06] 0.302
SEC high vs. ETA				0.70 [<0.01; 27.13] 0.821	0.24 [0.01; 5.45] 0.410	-0.06 [-0.18; 0.06] 0.302

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Others, n (%)	1 (10.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.00 [0.03; >999.99] 1.000	3.00 [0.14; 65.91] 1.000	0.10 [-0.09; 0.29] 0.292
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.2 Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Europe	21	23	16			
N' Others	10	5	10			
Musculoskeletal and connective tissue disorders						
Interaction test:	p=1.000					
Europe, n (%)	0 (0.0)	2 (8.7)	2 (12.5)			
SEC low vs. ETA				0.30 [<0.01; 3.99] 0.360	0.15 [0.01; 3.01] 0.180	-0.13 [-0.29; 0.04] 0.131
SEC high vs. ETA				0.67 [0.04; 10.31] 1.000	0.70 [0.11; 4.44] 1.000	-0.04 [-0.24; 0.16] 0.708
Others, n (%)	0 (0.0)	0 (0.0)	2 (20.0)			
SEC low vs. ETA				0.38 [<0.01; 5.23] 0.474	0.20 [0.01; 3.71] 0.474	-0.20 [-0.45; 0.05] 0.114
SEC high vs. ETA				0.78 [<0.01; 10.98] 0.857	0.37 [0.02; 6.46] 0.524	-0.20 [-0.45; 0.05] 0.114

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant ($p < 0.05$ in Fisher's exact test for RR).
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.3 Serious Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.4 Severe Adverse Events by SOC and PT, Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

S.5.5 Adverse Events of Special Interest, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Europe	21	23	16			
N' Others	10	5	10			
Infections and infestations (SOC)						
Interaction test:	p=0.810					
Europe, n (%)	16 (76.2)	18 (78.3)	12 (75.0)			
SEC low vs. ETA				1.06 [0.17; 6.20] 1.000	1.02 [0.70; 1.47] 1.000	0.01 [-0.27; 0.29] 0.934
SEC high vs. ETA				1.19 [0.19; 6.89] 1.000	1.04 [0.73; 1.49] 1.000	0.03 [-0.24; 0.30] 0.814
Others, n (%)	5 (50.0)	3 (60.0)	7 (70.0)			
SEC low vs. ETA				0.45 [0.05; 3.67] 0.650	0.71 [0.34; 1.50] 0.650	-0.20 [-0.62; 0.22] 0.351
SEC high vs. ETA				0.66 [0.04; 11.92] 1.000	0.86 [0.38; 1.95] 1.000	-0.10 [-0.61; 0.41] 0.703
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.744					
Europe, n (%)	2 (9.5)	6 (26.1)	1 (6.3)			
SEC low vs. ETA				1.56 [0.07; 99.27] 1.000	1.52 [0.15; 15.36] 1.000	0.03 [-0.14; 0.21] 0.710
SEC high vs. ETA				5.10 [0.52; 259.43] 0.242	4.17 [0.55; 31.42] 0.206	0.20 [-0.02; 0.41] 0.071
Others, n (%)	1 (10.0)	1 (20.0)	2 (20.0)			
SEC low vs. ETA				0.46 [<0.01; 10.51] 1.000	0.50 [0.05; 4.67] 1.000	-0.10 [-0.41; 0.21] 0.527
SEC high vs. ETA				1.00 [0.01; 25.35] 1.000	1.00 [0.12; 8.56] 1.000	0.00 [-0.43; 0.43] 1.000

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	2 (9.5)	1 (4.3)	1 (6.3)			
SEC low vs. ETA				1.56 [0.07; 99.27] 1.000	1.52 [0.15; 15.36] 1.000	0.03 [-0.14; 0.21] 0.710
SEC high vs. ETA				0.69 [<0.01; 57.05] 1.000	0.70 [0.05; 10.32] 1.000	-0.02 [-0.16; 0.13] 0.797
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Europe, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Others, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.5.6 Tanner Stage, Binary Analysis by Region (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=0.314**					
Europe, N / N'	**21 / 21**	**23 / 23**	**16 / 16**			
n (%)	18 (85.7)	19 (82.6)	15 (93.8)			
SEC low vs. ETA				0.41 [<0.01; 5.72] 0.826	0.91 [0.74; 1.13] 0.618	-0.08 [-0.27; 0.11] 0.410
SEC high vs. ETA				0.33 [<0.01; 3.75] 0.609	0.88 [0.70; 1.10] 0.631	-0.11 [-0.31; 0.08] 0.263
Others, N / N'	**10 / 10**	**5 / 5**	**10 / 10**			
n (%)	9 (90.0)	2 (40.0)	7 (70.0)			
SEC low vs. ETA				3.61 [0.23; 224.54] 0.582	1.29 [0.82; 2.03] 0.582	0.20 [-0.14; 0.54] 0.248
SEC high vs. ETA				0.31 [0.02; 4.29] 0.573	0.57 [0.18; 1.80] 0.329	-0.30 [-0.81; 0.21] 0.253
Pubertal at Week 52						
Interaction Test	**p=0.161**					
Europe, N / N'	**21 / 21**	**23 / 22**	**16 / 16**			
n (%)	18 (85.7)	19 (86.4)	15 (93.8)			
SEC low vs. ETA				0.41 [<0.01; 5.72] 0.826	0.91 [0.74; 1.13] 0.618	-0.08 [-0.27; 0.11] 0.410
SEC high vs. ETA				0.43 [<0.01; 6.01] 0.866	0.92 [0.75; 1.14] 0.624	-0.07 [-0.26; 0.11] 0.437
Others, N / N'	**10 / 8**	**5 / 5**	**10 / 7**			
n (%)	8 (100.0)	2 (40.0)	6 (85.7)			
SEC low vs. ETA				1.14 [0.03; N.E.] 0.933	1.17 [0.86; 1.58] 0.467	0.14 [-0.12; 0.40] 0.280
SEC high vs. ETA				0.14 [<0.01; 2.83] 0.303	0.47 [0.15; 1.42] 0.222	-0.46 [-0.96; 0.04] 0.074

Treatment Groups			Comparison		
SEC low (N=31)	SEC high (N=28)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.1 Adverse Events, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Weight < 50 kg	15	12	11			
N' Weight ≥ 50 kg	16	16	15			
Any AE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	12 (80.0)	10 (83.3)	10 (90.9)			
SEC low vs. ETA				0.41 [<0.01; 6.12] 0.852	0.88 [0.64; 1.21] 0.614	-0.11 [-0.37; 0.16] 0.418
SEC high vs. ETA				0.51 [<0.01; 11.42] 1.000	0.92 [0.67; 1.26] 1.000	-0.08 [-0.35; 0.20] 0.583
Weight ≥ 50 kg, n (%)	13 (81.3)	14 (87.5)	14 (93.3)			
SEC low vs. ETA				0.32 [<0.01; 4.59] 0.650	0.87 [0.66; 1.14] 0.600	-0.12 [-0.35; 0.11] 0.301
SEC high vs. ETA				0.51 [<0.01; 10.89] 1.000	0.94 [0.75; 1.18] 1.000	-0.06 [-0.26; 0.15] 0.578
Any SAE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	1 (6.7)	1 (8.3)	2 (18.2)			
SEC low vs. ETA				0.34 [<0.01; 7.35] 0.762	0.37 [0.04; 3.55] 0.556	-0.12 [-0.38; 0.15] 0.386
SEC high vs. ETA				0.43 [<0.01; 9.43] 0.932	0.46 [0.05; 4.38] 0.590	-0.10 [-0.37; 0.18] 0.485
Weight ≥ 50 kg, n (%)	2 (12.5)	2 (12.5)	3 (20.0)			
SEC low vs. ETA				0.58 [0.04; 5.99] 0.935	0.63 [0.12; 3.24] 0.654	-0.08 [-0.33; 0.18] 0.571
SEC high vs. ETA				0.58 [0.04; 5.99] 0.935	0.63 [0.12; 3.24] 0.654	-0.08 [-0.33; 0.18] 0.571

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	0 (0.0)	1 (8.3)	2 (18.2)			
SEC low vs. ETA				0.28 [<0.01; 3.80] 0.338	0.15 [0.01; 2.85] 0.169	-0.18 [-0.41; 0.05] 0.118
SEC high vs. ETA				0.43 [<0.01; 9.43] 0.932	0.46 [0.05; 4.38] 0.590	-0.10 [-0.37; 0.18] 0.485
Weight ≥ 50 kg, n (%)	1 (6.3)	1 (6.3)	2 (13.3)			
SEC low vs. ETA				0.44 [<0.01; 9.48] 0.950	0.47 [0.05; 4.65] 0.600	-0.07 [-0.28; 0.14] 0.506
SEC high vs. ETA				0.44 [<0.01; 9.48] 0.950	0.47 [0.05; 4.65] 0.600	-0.07 [-0.28; 0.14] 0.506
Any AE leading to study discontinuation						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	1 (6.7)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				0.73 [0.02; >999.99] 1.000	2.25 [0.10; 50.54] 1.000	0.07 [-0.06; 0.19] 0.301
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	1 (6.7)			
SEC low vs. ETA				0.94 [<0.01; 36.56] 0.968	0.31 [0.01; 7.15] 0.484	-0.07 [-0.19; 0.06] 0.301
SEC high vs. ETA				0.94 [<0.01; 36.56] 0.968	0.31 [0.01; 7.15] 0.484	-0.07 [-0.19; 0.06] 0.301

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.2 Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Weight < 50 kg	15	12	11			
N' Weight ≥ 50 kg	16	16	15			
Musculoskeletal and connective tissue disorders						
Interaction test:	p=0.171					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	3 (27.3)			
SEC low vs. ETA				0.16 [<0.01; 1.64] 0.127	0.11 [0.01; 1.88] 0.063	-0.27 [-0.54; -0.01] 0.042
SEC high vs. ETA				0.20 [<0.01; 2.07] 0.186	0.13 [0.01; 2.30] 0.093	-0.27 [-0.54; -0.01] 0.042
Weight ≥ 50 kg, n (%)	0 (0.0)	2 (12.5)	1 (6.7)			
SEC low vs. ETA				0.94 [<0.01; 36.56] 0.968	0.31 [0.01; 7.15] 0.484	-0.07 [-0.19; 0.06] 0.301
SEC high vs. ETA				1.96 [0.09; 126.29] 1.000	1.88 [0.19; 18.60] 1.000	0.06 [-0.15; 0.26] 0.578

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant ($p < 0.05$ in Fisher's exact test for RR).
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.3 Serious Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.4 Severe Adverse Events by SOC and PT, Binary Analysis by Weight (SAF)

There are no data meeting the display criteria for this table.

S.6.5 Adverse Events of Special Interest, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' Weight < 50 kg	15	12	11			
N' Weight ≥ 50 kg	16	16	15			
Infections and infestations (SOC)						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	10 (66.7)	8 (66.7)	8 (72.7)			
SEC low vs. ETA				0.76 [0.09; 5.42] 1.000	0.92 [0.55; 1.52] 1.000	-0.06 [-0.42; 0.29] 0.738
SEC high vs. ETA				0.76 [0.08; 6.23] 1.000	0.92 [0.53; 1.57] 1.000	-0.06 [-0.44; 0.31] 0.751
Weight ≥ 50 kg, n (%)	11 (68.8)	13 (81.3)	11 (73.3)			
SEC low vs. ETA				0.81 [0.12; 4.93] 1.000	0.94 [0.60; 1.47] 1.000	-0.05 [-0.36; 0.27] 0.778
SEC high vs. ETA				1.55 [0.21; 13.01] 0.921	1.11 [0.75; 1.63] 0.685	0.08 [-0.22; 0.37] 0.598
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=1.000					
Weight < 50 kg, n (%)	1 (6.7)	3 (25.0)	1 (9.1)			
SEC low vs. ETA				0.72 [<0.01; 61.62] 1.000	0.73 [0.05; 10.49] 1.000	-0.02 [-0.24; 0.19] 0.822
SEC high vs. ETA				3.17 [0.21; 192.16] 0.658	2.75 [0.33; 22.69] 0.590	0.16 [-0.14; 0.46] 0.296
Weight ≥ 50 kg, n (%)	2 (12.5)	4 (25.0)	2 (13.3)			
SEC low vs. ETA				0.93 [0.06; 14.61] 1.000	0.94 [0.15; 5.84] 1.000	-0.01 [-0.24; 0.23] 0.945
SEC high vs. ETA				2.11 [0.25; 27.43] 0.719	1.88 [0.40; 8.78] 0.654	0.12 [-0.16; 0.39] 0.403

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.541					
Weight < 50 kg, n (%)	2 (13.3)	1 (8.3)	0 (0.0)			
SEC low vs. ETA				1.85 [0.14; >999.99] 0.646	3.75 [0.20; 71.13] 0.492	0.13 [-0.04; 0.31] 0.129
SEC high vs. ETA				0.92 [0.02; >999.99] 1.000	2.77 [0.12; 61.66] 1.000	0.08 [-0.07; 0.24] 0.296
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	1 (6.7)			
SEC low vs. ETA				0.94 [<0.01; 36.56] 0.968	0.31 [0.01; 7.15] 0.484	-0.07 [-0.19; 0.06] 0.301
SEC high vs. ETA				0.94 [<0.01; 36.56] 0.968	0.31 [0.01; 7.15] 0.484	-0.07 [-0.19; 0.06] 0.301
Drug specific antibody present (PT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
Weight < 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Weight ≥ 50 kg, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.6.6 Tanner Stage, Binary Analysis by Weight (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=1.000**					
Weight < 50 kg, N / N'	**15 / 15**	**12 / 12**	**11 / 11**			
n (%)	11 (73.3)	6 (50.0)	8 (72.7)			
SEC low vs. ETA				1.03 [0.12; 8.14] 1.000	1.01 [0.63; 1.62] 1.000	0.01 [-0.34; 0.35] 0.973
SEC high vs. ETA				0.39 [0.04; 2.82] 0.494	0.69 [0.35; 1.35] 0.400	-0.23 [-0.61; 0.16] 0.249
Weight ≥ 50 kg, N / N'	**16 / 16**	**16 / 16**	**15 / 15**			
n (%)	16 (100.0)	15 (93.8)	14 (93.3)			
SEC low vs. ETA				1.07 [0.03; N.E.] 0.968	1.07 [0.94; 1.23] 0.484	0.07 [-0.06; 0.19] 0.301
SEC high vs. ETA				1.07 [0.01; 89.64] 1.000	1.00 [0.83; 1.21] 1.000	0.00 [-0.17; 0.18] 0.962
Pubertal at Week 52						
Interaction Test	**N.E.**					
Weight < 50 kg, N / N'	**15 / 15**	**12 / 11**	**11 / 9**			
n (%)	12 (80.0)	5 (45.5)	7 (77.8)			
SEC low vs. ETA				1.14 [0.08; 12.72] 1.000	1.03 [0.67; 1.58] 1.000	0.02 [-0.32; 0.36] 0.898
SEC high vs. ETA				0.26 [0.02; 2.28] 0.314	0.58 [0.28; 1.22] 0.197	-0.32 [-0.72; 0.08] 0.114
Weight ≥ 50 kg, N / N'	**16 / 14**	**16 / 16**	**15 / 14**			
n (%)	14 (100.0)	16 (100.0)	14 (100.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

Treatment Groups			Comparison		
SEC low (N=31)	SEC high (N=28)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.1 Adverse Events, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' No previous systemic therapy	6	9	10			
N' Previous systemic therapy	25	19	16			
Any AE						
Interaction test:	p=0.355					
No previous systemic therapy, n (%)	5 (83.3)	8 (88.9)	8 (80.0)			
SEC low vs. ETA				1.23 [0.05; 88.30] 1.000	1.04 [0.65; 1.67] 1.000	0.03 [-0.35; 0.42] 0.866
SEC high vs. ETA				1.93 [0.08; 132.51] 1.000	1.11 [0.75; 1.64] 1.000	0.09 [-0.23; 0.41] 0.588
Previous systemic therapy, n (%)	20 (80.0)	16 (84.2)	16 (100.0)			
SEC low vs. ETA				0.20 [<0.01; 1.60] 0.142	0.80 [0.66; 0.97] 0.137	-0.20 [-0.36; -0.04] 0.012
SEC high vs. ETA				0.28 [<0.01; 2.80] 0.296	0.84 [0.69; 1.02] 0.234	-0.16 [-0.32; 0.01] 0.059
Any SAE						
Interaction test:	p=0.657					
No previous systemic therapy, n (%)	1 (16.7)	1 (11.1)	1 (10.0)			
SEC low vs. ETA				1.73 [0.02; 156.75] 1.000	1.67 [0.13; 22.01] 1.000	0.07 [-0.28; 0.42] 0.710
SEC high vs. ETA				1.12 [0.01; 98.00] 1.000	1.11 [0.08; 15.28] 1.000	0.01 [-0.27; 0.29] 0.937
Previous systemic therapy, n (%)	2 (8.0)	2 (10.5)	4 (25.0)			
SEC low vs. ETA				0.27 [0.02; 2.20] 0.295	0.32 [0.07; 1.55] 0.187	-0.17 [-0.41; 0.07] 0.160
SEC high vs. ETA				0.36 [0.03; 3.02] 0.496	0.42 [0.09; 2.01] 0.379	-0.14 [-0.40; 0.11] 0.262

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE						
Interaction test:	p=0.348					
No previous systemic therapy, n (%)	1 (16.7)	1 (11.1)	1 (10.0)			
SEC low vs. ETA				1.73 [0.02; 156.75] 1.000	1.67 [0.13; 22.01] 1.000	0.07 [-0.28; 0.42] 0.710
SEC high vs. ETA				1.12 [0.01; 98.00] 1.000	1.11 [0.08; 15.28] 1.000	0.01 [-0.27; 0.29] 0.937
Previous systemic therapy, n (%)	0 (0.0)	1 (5.3)	3 (18.8)			
SEC low vs. ETA				0.15 [<0.01; 1.46] 0.105	0.09 [0.01; 1.70] 0.053	-0.19 [-0.38; 0.00] 0.055
SEC high vs. ETA				0.25 [<0.01; 3.53] 0.476	0.28 [0.03; 2.44] 0.312	-0.13 [-0.35; 0.08] 0.221
Any AE leading to study discontinuation						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Any AE leading to study drug discontinuation						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Previous systemic therapy, n (%)	1 (4.0)	0 (0.0)	1 (6.3)			
SEC low vs. ETA				0.63 [<0.01; 52.30] 1.000	0.64 [0.04; 9.52] 1.000	-0.02 [-0.16; 0.12] 0.755
SEC high vs. ETA				0.84 [<0.01; 32.84] 0.914	0.28 [0.01; 6.51] 0.457	-0.06 [-0.18; 0.06] 0.302

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.2 Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' No previous systemic therapy	6	9	10			
N' Previous systemic therapy	25	19	16			
Musculoskeletal and connective tissue disorders						
Interaction test:	p=1.000					
No previous systemic therapy, n (%)	0 (0.0)	1 (11.1)	1 (10.0)			
SEC low vs. ETA				1.67 [<0.01; 65.00] 1.000	0.52 [0.02; 11.14] 1.000	-0.10 [-0.29; 0.09] 0.292
SEC high vs. ETA				1.12 [0.01; 98.00] 1.000	1.11 [0.08; 15.28] 1.000	0.01 [-0.27; 0.29] 0.937
Previous systemic therapy, n (%)	0 (0.0)	1 (5.3)	3 (18.8)			
SEC low vs. ETA				0.15 [<0.01; 1.46] 0.105	0.09 [0.01; 1.70] 0.053	-0.19 [-0.38; 0.00] 0.055
SEC high vs. ETA				0.25 [<0.01; 3.53] 0.476	0.28 [0.03; 2.44] 0.312	-0.13 [-0.35; 0.08] 0.221

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Subgroup analysis of SOCs and PTs is displayed only if the main effect in the total population is significant ($p < 0.05$ in Fisher's exact test for RR).
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.3 Serious Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.4 Severe Adverse Events by SOC and PT, Binary Analysis by Previous Systemic Therapy (SAF)

There are no data meeting the display criteria for this table.

S.7.5 Adverse Events of Special Interest, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	31	28	26			
N' No previous systemic therapy	6	9	10			
N' Previous systemic therapy	25	19	16			
Infections and infestations (SOC)						
Interaction test:	p=1.000					
No previous systemic therapy, n (%)	5 (83.3)	7 (77.8)	8 (80.0)			
SEC low vs. ETA				1.23 [0.05; 88.30] 1.000	1.04 [0.65; 1.67] 1.000	0.03 [-0.35; 0.42] 0.866
SEC high vs. ETA				0.88 [0.05; 15.26] 1.000	0.97 [0.61; 1.55] 1.000	-0.02 [-0.39; 0.35] 0.906
Previous systemic therapy, n (%)	16 (64.0)	14 (73.7)	11 (68.8)			
SEC low vs. ETA				0.81 [0.17; 3.65] 1.000	0.93 [0.60; 1.45] 1.000	-0.05 [-0.34; 0.25] 0.752
SEC high vs. ETA				1.26 [0.23; 7.11] 1.000	1.07 [0.70; 1.64] 1.000	0.05 [-0.25; 0.35] 0.748
Hypersensitivity (SMQ) (narrow)						
Interaction test:	p=0.625					
No previous systemic therapy, n (%)	1 (16.7)	1 (11.1)	1 (10.0)			
SEC low vs. ETA				1.73 [0.02; 156.75] 1.000	1.67 [0.13; 22.01] 1.000	0.07 [-0.28; 0.42] 0.710
SEC high vs. ETA				1.12 [0.01; 98.00] 1.000	1.11 [0.08; 15.28] 1.000	0.01 [-0.27; 0.29] 0.937
Previous systemic therapy, n (%)	2 (8.0)	6 (31.6)	2 (12.5)			
SEC low vs. ETA				0.62 [0.04; 9.40] 1.000	0.64 [0.10; 4.10] 0.637	-0.05 [-0.24; 0.15] 0.649
SEC high vs. ETA				3.13 [0.45; 37.11] 0.352	2.53 [0.59; 10.83] 0.244	0.19 [-0.07; 0.46] 0.157

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Neutropenia (NMQ) (narrow)						
Interaction test:	p=0.609					
No previous systemic therapy, n (%)	1 (16.7)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				1.67 [0.04; >999.99] 0.750	4.71 [0.22; 100.26] 0.375	0.17 [-0.13; 0.46] 0.273
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	1 (4.0)	1 (5.3)	1 (6.3)			
SEC low vs. ETA				0.63 [<0.01; 52.30] 1.000	0.64 [0.04; 9.52] 1.000	-0.02 [-0.16; 0.12] 0.755
SEC high vs. ETA				0.84 [0.01; 69.73] 1.000	0.84 [0.06; 12.42] 1.000	-0.01 [-0.17; 0.15] 0.901
Drug specific antibody present (PT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Hepatitis viral infections (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Inflammatory bowel disease (NMQ) (narrow)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
MACE (MI, Stroke, Cardiovascular death) (NMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Malignant or unspecified tumours (SMQ)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.
Vaccination related complications (HLT)						
Interaction test:	N.E.					
No previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Previous systemic therapy, n (%)	0 (0.0)	0 (0.0)	0 (0.0)			
SEC low vs. ETA				N.E.	N.E.	N.E.
SEC high vs. ETA				N.E.	N.E.	N.E.

N': Number of patients in the analysis
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup.
Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.

S.7.6 Tanner Stage, Binary Analysis by Previous Systemic Therapy (SAF)

	Treatment Groups			Comparison		
	SEC low (N=31)	**SEC high (N=28)**	**ETA (N=26)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Pubertal at Baseline						
Interaction Test	**p=1.000**					
No previous systemic therapy, N / N'	**6 / 6**	**9 / 9**	**10 / 10**			
n (%)	5 (83.3)	7 (77.8)	8 (80.0)			
SEC low vs. ETA				1.23 [0.05; 88.30] 1.000	1.04 [0.65; 1.67] 1.000	0.03 [-0.35; 0.42] 0.866
SEC high vs. ETA				0.88 [0.05; 15.26] 1.000	0.97 [0.61; 1.55] 1.000	-0.02 [-0.39; 0.35] 0.906
Previous systemic therapy, N / N'	**25 / 25**	**19 / 19**	**16 / 16**			
n (%)	22 (88.0)	14 (73.7)	14 (87.5)			
SEC low vs. ETA				1.05 [0.08; 10.38] 1.000	1.01 [0.80; 1.27] 1.000	0.01 [-0.20; 0.21] 0.962
SEC high vs. ETA				0.41 [0.03; 3.05] 0.559	0.84 [0.61; 1.17] 0.415	-0.14 [-0.39; 0.12] 0.290
Pubertal at Week 52						
Interaction Test	**p=0.039**					
No previous systemic therapy, N / N'	**6 / 5**	**9 / 9**	**10 / 8**			
n (%)	3 (60.0)	8 (88.9)	7 (87.5)			
SEC low vs. ETA				0.24 [<0.01; 6.39] 0.629	0.69 [0.32; 1.47] 0.510	-0.28 [-0.76; 0.21] 0.268
SEC high vs. ETA				1.13 [0.01; 100.78] 1.000	1.02 [0.72; 1.44] 1.000	0.01 [-0.29; 0.32] 0.930
Previous systemic therapy, N / N'	**25 / 24**	**19 / 18**	**16 / 15**			
n (%)	23 (95.8)	13 (72.2)	14 (93.3)			
SEC low vs. ETA				1.62 [0.02; 134.48] 1.000	1.03 [0.88; 1.20] 1.000	0.03 [-0.12; 0.17] 0.743
SEC high vs. ETA				0.19 [<0.01; 2.08] 0.266	0.77 [0.56; 1.06] 0.186	-0.21 [-0.45; 0.03] 0.088

	Treatment Groups			Comparison		
	SEC low (N=31)	SEC high (N=28)	ETA (N=26)	OR [95% CI] p-value	RR [95% CI] p-value	RD [95% CI] p-value

N': Number of patients with available response value
n (%): Number and percentage of patients with event
CI: Confidence Interval
N.E.: Not estimable
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference

Interaction test from exact logistic regression model with predictors treatment, subgroup and treatment x subgroup, OR (with CI and p-value) from separate exact logistic regression models for each subgroup with treatment as predictor.
RR and RD calculated directly within subgroups (with Wald CI), p-values from Fisher's exact test for RR and from Wald test for RD.

Subgroup analysis is displayed for subgrouping factors with at least 10 patients in each subgroup. In addition, for binary parameters, subgroup analysis is displayed only if there are at least 10 events in at least one subgroup.

Interaction test, OR, RR and RD are N.E. if the incidence of events is zero or 100% in all involved subgroup*treatment groups.